
contributed to the pathogenesis of DN (Roy et al., 2010). CoQ10, NAC or their combination treatment restored serum total protein and albumin by preventing their urinary excretion. The combination treatment with CoQ10 and NAC in diabetic rats was found more effective than CoQ10 or NAC alone in restoration of serum total proteins and albumin.

The most common characteristics in the development of DN are the elevated serum creatinine (SCr) and declined creatinine clearance (Ccr) (Dabla, 2010). The present study showed the significant elevation in the SCr, and decline in CCr in diabetic groups than normal rats pointing to the declined renal function and development of DN. However, diabetic rats that received CoQ10 (10 mg/kg), NAC (300 mg/kg) or their combination decreased SCr and improved CCr, particularly in the animals treated with the combination of the antioxidants. In addition to the chronic hyperglycaemia, polyuria is another feature of DM arising from osmotic diuresis. The significant increment in the urine output (mL/day) noted in this study may be due to glucosuria associated osmotic diuresis. In this study, severe renal impairment in the diabetic rats was identified by substantial rise in the urinary total proteins and UAER. Decreased serum albumin and increased UAER in diabetic complications were linked to the rapid progression of renal disease.

Earlier reports demonstrated that DM induced renal dysfunction is associated with a gradual reduction in serum albumin level. Albuminuria, resulting from damage to the glycosaminoglycans in the basement membrane and increased pore size may be linked to the decreased serum albumin (Mora-Fernández et al., 2014; Haraldsson & Sörensson, 2004). Consequently, the reduction of proteinuria could be beneficial for improving renal function and to prevent the progression of DN towards ESRD (Oktem et al., 2006). Combined oral administration of CoQ10 and NAC to the diabetic rats was found effective in reversing the urinary protein loss declining UAER.

OS is the key element in the development and progression of DN and associated renal injury. Diabetic state is believed to induce OS by an imbalance between the normal antioxidant defense and elevated ROS production. It has been shown that antioxidant treatment in DN improves renal function by directly acting against oxidative tissue damage (Mahajan et al., 2019). Moreover, exogenous administration of antioxidants restricts the progression of DN by effective inhibition of ROS and scavenging the preformed intracellular ROS (Agrawal & Sadhukhan, 2015).

We noted impaired oxidative stability in diabetic rats as indicated by the elevated MDA level and reduced activity of antioxidant enzymes SOD and CAT. It is believed that during DM hyperglycaemia-induced OS increases lipid peroxidation (Idris et al., 2001). MDA, the product of lipid peroxidation is responsible for the cellular injury. As an aldehyde, MDA links sugar and protein to form glycated proteins. Such structural and functional abnormalities in proteins might be responsible for diabetic complications. Thus, increased levels of HbA_{1c} may have some linkages with increased lipid peroxidation (Krhač & Lovrenčić, 2019). There was a considerable decrease in lipid peroxidation and an elevation in SOD, CAT activity, along with increased GSH content in the renal tissue of rats treated orally with a combination of CoQ10 and NAC.

Studies correlated MPO and DM with a positive relationship between the raised MPO activity and the pathogenesis of DN (Rovira-Llopis et al., 2013). The MPO-hydrogen, a peroxidechloride system, leads to a variety of chlorinated protein and lipid adducts that may cause dysfunction in the different compartments of the kidney (Prabhakar, 2004). In the present study, oral combination therapy of diabetic rats with CoQ10 and NAC significantly reduced renal MPO activity in the renal tissue than the CoQ10 and NAC alone treated rats.

NO is implicated in pathogenesis of DN since it modulates renal structure and function. In diabetes, abnormal NO production is linked to the progression of the kidney damage. Studies showed that most of the cytotoxicity attributed to NO is due to peroxynitrite, produced from the reaction between NO and the superoxide anion (Stamler et al., 1992; Kisic et al., 2016). In the present study, there was a significant elevation in nitrite content in the renal tissue of diabetic rats as compared to the normal rats. However, the diabetic rats treated with a combination of CoQ10 and NAC effectively reduced renal nitrite levels.

In conclusion, the results presented in this study provide valuable information supporting that treatment with antioxidants might prevent or delay the renal damage associated with DN. Oral administration of antioxidants, that is, CoQ10 and NAC possesses a significant nephroprotective effect against STZ-NAD induced DN. A combination therapy with CoQ10 and NAC is more promising as it improves renal function and reduces OS in the rats subjected to DN. Nephroprotective effect shown by the combination treatment in this study may be attributed to hypoglycaemic and antioxidant properties of these compounds that attenuated OS and enhanced renal function in diabetic rats. Finally, it was concluded that the combined administration of CoQ10 with NAC might attenuate or delay the progression of DN.

ABBREVIATIONS

AGEs: Advanced glycation end products ANOVA: Analysis of variance ATP: Adenosine triphosphate BUN: Blood urea nitrogen CAT: Catalase CoQ10: Coenzyme Q10 DM: Diabetes mellitus DN: Diabetic nephropathy GLUT2: Glucose transporter 2 GSH: Reduced glutathione h: Hour HbA_{1c}: Glycated haemoglobin
i.p.: Intraperitoneal
MDA: Malondialdehyde
MPO: Myeloperoxidase
NAC: N-acetylcysteine
NAD: Nicotinamide
NIDDM: Non-insulin-dependent diabetes mellitus
NO: Nitric oxide

References

- Agarwal N, Sadhukhan P. Therapeutic Insights against Oxidative Stress Induced Diabetic Nephropathy: A Review. J Autoimmune Disord. 2015; 1: 1–17.
- [2] Ahmad A, Mondello S, Di Paola R et al. Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrastinduced nephropathy in the diabetic rats: A comparison with n-acetylcysteine. Eur J Pharmacol. 2012; 674: 397–406.
- [3] Ahmadi A, Mazooji N, Roozbeh J, Mazloom Z, Hasanzade J. Effect of alpha-lipoic acid and vitamin E supplementation on oxidative stress, inflammation, and malnutrition in hemodialysis patients. Iran J Kidney Dis. 2013; 7: 461–467.
- [4] Ahmadvand H. Effects of coenzyme Q10 on hemoglobin A1C, serum urea and creatinine in alloxan-induced Type 1 diabetic rats. Iran J Pharmacol Ther. 2012; 11: 64–67.
- [5] Alam M, Rahman M. Mitochondrial dysfunction in obesity: Potential benefit and mechanism of co-enzyme Q10 supplementation in metabolic syndrome. J Diabetes Metab Disord. 2014; 13: 1–11.
- [6] Algenstaedt P, Schaefer C, Biermann T, et al. Microvascular Alterations in Diabetic Mice Correlate with Level of Hyperglycemia. Diabetes. 2003; 52: 542–549.
- [7] Amin M, Asaad G, Abdel Salam R, El-Abhar H, Arbid M. Novel CoQ10 Antidiabetic Mechanisms Underlie Its Positive Effect: Modulation of Insulin and Adiponectine Receptors, Tyrosine Kinase, PI3K, Glucose Transporters, sRAGE and Visfatin in Insulin Resistant/Diabetic Rats. PLoS One. 2014; 9: e89169.
- [8] Ammon HP, Muller PH, Eggstein M, Wintermantel C, Aigner B, Safayhi H, et al. Increase in glucose consumption by acetylcysteine during hyperglycemic clamp. A study with healthy volunteers. Arzneimittelforsch. 1992; 42: 642–645.
- [9] Anwar M, Abd El-Moniem M, Megahed H, EL-Toukhy S, Mohammed N, Youness E. Effect of Coenzyme Q10 Supplementation on Markers of Oxidative Stress in Streptozotocin Induced Diabetic Rats. *Journal of Applied Pharmaceutical Science*. 2014; 4: 9–15.
- [10] Ates O, Bilen H, Keles S, Alp H, Keles M, et al. Plasma coenzyme Q10 levels in type 2 diabetic patients with retinopathy. Int J Ophthalmol. 2013; 6: 675–679.
- [11] Badole SL, Bagul PP, Mahamuni SP et al. Oral L-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in streptozotocin-nicotinamide induced diabetic rats. ChemBiol Interact. 2013; 203: 530–541.
- [12] Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414: 813–20.

OS: Oxidative stress p.o.: Per oral PKC: Protein kinase C ROS: Reactive oxygen species SEM: Standard error of the mean SOD: Superoxide dismutase STZ: streptozotocin T2DM: Type-2 diabetes mellitus

- [13] Dabla PK. Renal function in diabetic nephropathy. World J Diabetes. 2010; 1:48–56.
- [14] Garjani A, Andalib S, Biabani S, Soraya H, Doustar Y, et al. Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. Eur J Pharmacol. 2011; 666: 135–141.
- [15] Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med. 2009; 15: 1298–1306.
- [16] Ghasemi A, Khalifi S, Jedi S. Streptozotocin-nicotinamide induced rat model of type 2 diabetes. Acta Physiol Hung. 2014; 101:408–420.
- [17] Haber CA, Lam TK, Yu Z et al. N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress. Am J Physiol Endocrinol Metab. 2003; 285: E744– E753.
- [18] Haraldsson B, Sörensson J. Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol Sci. 2004; 19: 7–10.
- [19] Hasegawa G, Yamamoto Y, Zhi J, Tanino Y, Yamasaki M, et al. Daily profile of plasma %CoQ10 level, a biomarker of oxidative stress, in patients with diabetes manifesting postprandial hyperglycaemia. Acta Diabetol. 2005; 42: 179–181.
- [20] Ho E, Chen G, Bray TM. Supplementation of N-acetylcysteine inhibits NF-kappaB activation and protects against alloxaninduced diabetes in CD-1 mice. FASEB J. 1999; 13: 1845–1854.
- [21] Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: A controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002; 56: 1137–1142.
- [22] Idris I, Gray S, Donnelly R. Protein kinase C activation: isozymespecific effects on metabolism and cardiovascular complications in diabetes. Diabetologia. 2001; 44: 659–673.
- [23] Jemai H, El Feki A, Sayadi S. Antidiabetic and antioxidant effects of hydroxytyrosol and oleuropein from olive leaves in alloxandiabetic rats. J Agric Food Chem. 2009; 57: 8798–8804.
- [24] Kisic B, Miric D, Dragojevic I, Rasic J, Popovic L. Role of Myeloperoxidase in Patients with Chronic Kidney Disease. Oxid Med Cell Longev. 2016; 1–10.
- [25] Kohei KA. Pathophysiology of type 2 diabetes and its treatment policy. JMAJ. 2010; 53: 41-46.
- [26] Krhač M, Lovrenčić MV. Update on biomarkers of glycemic control. World J Diabetes. 2019; 10: 1–15.

Nephroprotective Effect of Coenzyme Q10 alone and in Combination with N-acetylcysteine ...

- [27] Lee ES, Kim HM, Kang JS, Lee EY, et al. Oleanolic acid and N-acetylcysteine ameliorate diabetic nephropathy through reduction of oxidative stress and endoplasmic reticulum stress in a type 2 diabetic rat model. Nephrol Dial Transplant. 2016; 3: 391–400.
- [28] Mahajan MS, Gulecha VS, Upaganlawar AB, Upasani CD. Antioxidant Defense in Diabetic Nephropathy In: Uddin S & Upaganlawar AB: Oxidative Stress and Antioxidant Defense: Biomedical value in Health and Diseases, 1st ed. New York: Nova; 2019.
- [29] Maheshwari R, Balaraman R, Sen AK, Shukla D, Seth A. Effect of concomitant administration of coenzyme Q10 with sitagliptin on experimentally induced diabetic nephropathy in rats. Renal Failure. 2017; 39: 130–139.
- [30] Maheshwari RA, Balaraman R, Sen AK, Seth AK. Effect of coenzyme Q10 alone and its combination with metformin on streptozotocin-nicotinamide-induced diabetic nephropathy in rats. Indian J Pharmacol. 2014; 46: 627–32.
- [31] Maitra A. The Endocrine System. in: Kumar V, Abbas A, Fausto N, Aster J. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia: Elsevier Saunders; 2015.
- [32] Masharani, U. Diabetes Mellitus and hypoglycemia. In: McPhee SJ, Papadakis MA, Tierney LM. Current medical diagnosis and treatment, 47th ed. New York: McGraw-Hill; 2008.
- [33] Mezawa M, Takemoto M, Onishi S, Ishibashi R, Ishikawa T, Yamaga, M, et al. The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study. Biofactors. 2012; 38: 416–421.
- [34] Midaoui A, Ismael M, Lu H, Fantus I, de Champlain J, Couture R. Comparative effects of N-acetyl-L-cysteineand ramipril on arterial hypertension, insulin resistance, andoxidative stress in chronically glucose-fed rats. Can J Physiol Pharmacol. 2008; 86: 752–60
- [35] Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease. Origin and development of ideas. Diabetologia. 1999; 42: 263–285.
- [36] Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983; 32: 64–78.
- [37] Mora-Fernández C, Domínguez-Pimentel V, de Fuentes MM, et al. Diabetic kidney disease: from physiology to therapeutics. J Physiol. 2014; 592: 3997–4012.
- [38] Odetti P, Pesce C, Traverso N, Menini S, Maineri EP, et al. Comparative trial of N-acetyl-cysteine, taurine, and oxerutin on skin and kidney damage in long-term experimental diabetes. Diabetes. 2003; 52: 499–505.
- [39] Oktem F, Ozguner F, Yilmaz HR, et al. Melatonin reduces urinary excretion of N-acetyl-beta–D-glucosaminidase, albumin and renal oxidative markers in diabetic rats. Clin Exp Pharmacol Physiol. 2006; 33: 95–101.
- [40] Pal PB, Sinha K, Sil PC. Mangiferin attenuates diabetic nephropathy by inhibiting oxidative stress mediated signaling cascade, TNFα related and mitochondrial dependent apoptotic pathways in streptozotocin-induced diabetic rats. PLoS One. 2014; 9: e107220.

- [41] Prabhakar SS. Role of nitric oxide in diabetic nephropathy. Semin Nephrol. 2004; 24: 333–344.
- [42] Rajkumar L, Govindarajulu P. Increased degradation of dermal collagen in diabetic rats. Indian J Exp Bio. 1991; 29: 1081–1083.
- [43] Rajkumar V, Ragatzki P, Sima A, Levy J. Enhanced platelet aggregation, high homocysteine level, and microvascular disease in diabetic muscle infaractions. Endocrine. 1999; 11: 57–60.
- [44] Rosenfeldt FL, Haas SJ, Krum H. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007; 21: 297–306.
- [45] Rovira-Llopis S, Rocha M, Victor M et al. Is myeloperoxidase a key component in the ROS-induced vascular damage related to nephropathy in type 2 diabetes?" ARS. 2013; 19: 1452–1458.
- [46] Roy S, Trudeau K, Roy S, Behl Y, Dhar S, Chronopoulos A. New insights into hyperglycemia-induced molecular changes in microvascular cells. J Dent Res. 2010; 89: 116–128.
- [47] Schena FP and Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. 2010; 16: 30–33.
- [48] Shimizu MH, Coimbra TM, de Araujo M et al. N-acetylcysteine attenuates the progression of chronic renal failure.Kidney Int. 2005; 68: 2208–2217.
- [49] Sourris K, Harcourt B, Tang P, Morley A, Huynh K, et al. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med. 2012; 52: 716–723.
- [50] Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science. 1992; 258: 1898–902.
- [51] Teoh SL, Abdulatiff A, Das S. Histological changes in the kidneys of experimental diabetic rats fed with Momordicalcharantia (bitter gourd) extract. Rom J MorpholEmbryol. 2010; 51: 91–5.
- [52] Vasavada N and Agarwal R. Role of Oxidative Stress in Diabetic Nephropathy. Adv Chronic Kidney Dis. 2005; 12: 146–154.
- [53] Vora JP and Ibrahim HAA. Clinical manifestations and natural history of diabetic nephropathy. In: Johnson R and Feehally J: Comprehensive clinical nephrology, 2nd ed. Edinburgh: Mosby; 2003.
- [54] Zhang X, Shi Z, Liu Q, Quan H, Cheng X. Effects of coenzyme Q10 intervention on diabetic kidney disease. Medicine. 2019; 98: 1–18.

EUROPEAN PHARMACEUTICAL JOURNAL



Evaluation of variability of silymarin complex in Silybi mariani fructus harvested during two production years

Original Paper

Habán M.^{1,2^{ICI}}, Zvercová D.², Adamjaková M.¹

¹Comenius University in Bratislava, Faculty of Pharmacy, Department of Pharmacognosy and Botany ²Slovak University of Agriculture in Nitra, Faculty of Agrobiology and Food Resources, Department of Sustainable Agriculture and Herbology

Received 24 January, 2021, accepted 28 April, 2021

Abstract Milk thistle [*Silybum marianum* (L.) Gaertn.], a member of *Asteraceae* family, is one of the most cultivated medicinal plants widespread throughout the world. The pharmacological drug is a ripe fruit without pappus – Silybi mariani fructus – containing flavonolignans and generating silymarin complex. In folk medicine, it is used for the treatment of liver disorders, kidney problems, rheumatism as well as gastronomic disturbances, cardiac and neurotic disorders, and fever. The components of silymarin complex are useful in cancer prevention and treatment. The aim of the study was to determine the amount of silymarin complex contained in the fruit of the harvest of two consecutive years and how much they differ from one another. Representative samples of fruit were collected in 2015 and 2016 and distributed by a company Agrofos (Slovakia). Regarding the analytical method, we used a high-performance liquid chromatography (HPLC); the method was approved by the European Pharmacopoeia 10. The statistical significance was on the level *P* < 0.05. The total content of silymarin complex was 15.28 ± 0.06 g.kg⁻¹ (in 2015). In both studied years, the highest representation of silymarin complex were statistically significant. There was also a significant differences between the individual fractions of the silymarin complex were statistically significant. There was also a significant difference of 9% in the total silymarin content between 2015 and 2016. In conclusion, we can state that both samples of Silybi mariani fructus meet the requirements of the European Pharmacopoeia.

Keywords Silybum marianum – silymarin complex – HPLC

INTRODUCTION

Milk thistle [*Silybum marianum* (L.) Gaertn.] belongs to the *Asteraceae* family. This plant, originated in the Mediterranean region, is widespread throughout the world and has been grown throughout Europe, Africa, China, India and Australia for centuries (Polyak et al., 2013). Ražná et al. (2015) stated that it is one of the most cultivated medicinal plants on the Slovak market. It was cultivated on more than 1000 hectares in 2014 and 2015. The pharmacological drug forms ripe fruit without pappus, known as Silybi mariani fructus (Nagy et al., 2015). The fruits are achenes, dark brown to black colour, mostly flattened and oval. The length of the fruit ranges from 5 to 7 mm, width from 2 to 3 mm and thickness is about 1.5 mm (Abenavoli et al., 2010). During the harvest, the entire flower heads are cut, even with inflorescence, just before the fruit ripens. Obtained fruits are rich in flavonoids, which are concentrated

in the pericarp and seed (Andrzejewska et al., 2011; Giuliani et al., 2018). These biologically active phytochemicals, flavonolignans (silybin A and silybin B, isosilybin A and isosilybin B, silydianin, silychristin, isosilychristin and others) and flavonoid taxifolin are collectively known as silymarin (Pendry et al., 2017). The silymarin complex forms 60%–80% of the extract of Silybi mariani fructus. The silymarin content most often ranges from 1% to 3% of dry matter, but can exceed 8% (Karkanis et al., 2011; Lucini et al., 2015). When isolated from fruit, a multi-stage purification takes place, including extraction with ethyl acetate. This is an achieved enrichment of pharmacologically active flavonoids, while neutral or undesirable components are removed (Jedlinszki et al., 2016). Silymarin and its flavonolignans are commercially available in various formulations containing fruit extracts such as liquid

^{*} E-mail: haban@fpharm.uniba.sk, miroslav.haban@uniag.sk ORCID: 0000-0002-8013-0088.

³ Open Access. © 2021 European Pharmaceutical Journal, published by Sciendo. CC) BY-NC-ND This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

extracts, capsules and tablets as well as in combination with synthetic chemical drugs or other herbal materials (Elateeg et al., 2020). Silybi mariani fructus are used as a medicine for hemorrhoids and heart disorders (Ghorbani, 2005), while roots and stems are used as a medicine for blood pressure and fever (Mirdeilami et al., 2011). The plant has a long history as a medicinal plant in folk medicine used for the treatment of liver disorders, kidney problems, rheumatism, gastronomic disturbances, cardiac disorders and fever (Marmouzi et al., 2021). Qin et al. (2017) found out that the silymarin also shows antioxidant and anti-diabetic activities. It was shown to be a putative neuroprotective agent against many neurological diseases including Alzheimer's and Parkinson's diseases and cerebral ischaemia (Borah et al., 2013). In addition, silymarin possesses antioxidant, anti-inflammatory and anti-fibrotic properties. It stimulates the biosynthesis of proteins, increases lactation and possesses immune-modulation activity (Abenavoli et al., 2010). Silymarin also shows in vitro efficacy as a cancer chemopreventive agent by arresting human prostate carcinoma proliferation in cancer cell cultures (Tyagi et al., 2002) and in human cancer models (Singh et al., 2002). Silybin, one of the constituents of silymarin, was included in the list of molecules useful in a broad-spectrum integrative approach for cancer prevention and treatment (Block et al., 2015). The anticancer efficacy of silybin is exerted through its ability to affect cancer cell proliferation and metabolism, inflammation and angiogenesis (Deep & Agarwal, 2010). Silibinin clearly demonstrates the inhibition of multiple cancer cell signalling pathways, including a growth inhibition, inhibition of angiogenesis, chemosensitization and the inhibition of invasion and metastasis. The cumulative evidence implicates that silibinin is a potential agent for a cancer chemoprevention and chemotherapy (Li et al., 2010). Several studies have reported a beneficial effect of silymarin in different experimental models of acute and chronic inflammation, for example, in rats with formalin-induced paw oedema (Alhadidi et al., 2009). The findings by Li et al. (2016) demonstrate that silymarin is able to attenuate the airway inflammation induced by a cigarette smoke extract in human bronchial epithelial cells. Ripe seeds contain a large amount of oil (approximately 200-300 g.kg⁻¹). Although it contains a relatively high amount of fatty acids (linoleic, linolenic, oleic and arachidic acid), it is a by-product of the industrial production of silymarin and must be removed from seeds before the extraction. Relatively large amounts of strongly lipophilic organic solvents, most often hexane or petroleum ether, are used for degreasing. The oil from milk thistle is used in foods and pharmaceutical industries, but due to ineffective reasons of exploitation and lack of cost-effective technologies, it is relatively rare on the market (Abouzid et al., 2016; Mei et al., 2013). The total yield of milk thistle and silymarin varies depending on environmental conditions, genotypes, sowing and harvest dates as well as gaps between rows and different farming practices (Karkanis et al., 2011).

METHODS

For this experiment, we used representative samples of fruit collected in 2015 and 2016 and distributed by the company Agrofos (Slovakia). The samples were analysed according to the guidelines of the European Pharmacopoeia (Ph. Eur. 10), which were partially modified by the methodological procedure. High-performance liquid chromatography method (HPLC) was applied to evaluate the silymarin complex of Silybi mariani fructus, using Agilent 1200 Infinity system. The research was carried out at the Department of Sustainable Agriculture and Herbology of Slovak University of Agriculture in Nitra.

The samples were ground in a grinder and 5 g was placed in the apparatus for continual extraction. We added 100 ml of petroleum ether and let it heat in a water bath for 8 hours. We added 100 ml of methanol to the sample and placed it in the apparatus where it was extracted in a water bath for another 5 hours. After the evaporation of the methanol extract, the sample was concentrated to a volume of about 30 ml. The extraction flask and filter were washed with methanol, and the extract was filled in up to 50 ml. Consequently, we prepared the reference solution by dissolving the dried thistle extract and by diluting the sample to 100 ml with the same solvent.

The following were the HPLC conditions: column with length I = 0.125 m and with diameter = 4 mm; stationary phase – 5 μ m silica gel end-capping octadecylsilyl; mobile phase – a mixture of phosphoric acid, methanol and water (0.5:35:65), and a mixture of phosphoric acid, methanol and water (0.5:50:50) with the flow 0.8 ml.min⁻¹. The detection was carried out by spectrophotometer at 288 nm and injection volume 10 μ l.

Concerning the identification of silymarin complex fractions, we used the record from the chromatogram of the dried milk thistle's extract and from the chromatogram of the reference solution to correctly identify the area and height of the peaks for silychristin, silydianin, silybin A, silybin B and isosilybin A + B (Fig. 1). The peak areas of the respective diastereomers were calculated by the percentage of the total peak area of a known concentration of the isomeric flavonolignan mixture. To obtain the results, we calculated the specific weights of flavonolignans presenting the proportional relations between the individual peak areas and their corresponding applied quantity.

The statistical evaluation of data was carried out by using the program STATISTICA CZ version 10 and ANOVA main effects by means of Fisher's LSD test at the statistical significance level $\alpha = 0.05$.

RESULTS

Concerning the experimental part of presented study, two parallel analyses and measurements were performed in four repetitions. There were 6 major flavonolignans (silychristin, silydianin, silybin A, silybin B, isosilybin A and isosilybin B) in the silymarin complex of the analysed samples. Individual components of the silymarin complex were identified by the size of the peaks detected by HPLC analysis (Fig. 2) and converted to g.kg⁻¹. The results are reported as mean \pm standard deviation (SD) and median. In each observed year, the differences between the representations of individual components of the silymarin complex were statistically significant (*P* < 0.05). In a sample of Silybi mariani fructus collected in 2015 (Table 1), the value of silybin B was twice as high as the value of silybin A. The common value of isosilybin



Figure 1. Chromatogram of Silybi mariani fructus according to the European Pharmacopoeia 10.

A and isosilybin B was the second most abundant silymarin fraction. This was followed by silydianin with the smallest average value in the set of silymarin components; the lowest measured value of this component being 0.88 g.kg⁻¹ and the highest 0.96 g.kg⁻¹. Analogous results were achieved in 2016 (Table 2), when the highest proportion of silybin B component was achieved. Compared to the previous year, it was lower by 1.12 g.kg⁻¹. The amount of silychristin in 2016 ranged from 4.40 g.kg⁻¹ to 3.79 g.kg⁻¹. The average value of silybin A was lower by 0.10 g.kg⁻¹ compared to 2015, while the common value of isosilybin A + B fractions increased by 0.89 g.kg⁻¹. This year was also recorded the lowest value of the silydianin component. Its amount ranged from 1.56 g.kg⁻¹ to 1.94 g.kg⁻¹. Between 2015 and 2016, the period monitored in terms of qualitative production of Silybi mariani fructus for the determination of silymarin, there was a significant difference (P < 0.05) in observed values. The results showed that after counting all silymarin components, the silymarin complex was 1.37 g.kg⁻¹ higher in 2016 than in 2015. This represents a difference of 9%. After evaluating the ratio of individual fractions, we can state that we did not work with samples of fruit of different chemotypes.

DISCUSION

In a scientific study carried out by Wianovska and Wiśniewski (2015), a pressurized liquid extraction to prepare samples was used. This isolated the silymarin mixture in a one-step extraction process and, therefore, reduced the extraction time and volumes of solvents used. Using this method, the total content of the silymarin complex was 22.7 g.kg⁻¹ (2.27%). Compared to values in presented study, there was a difference of 0.74% concerning fruit collected in 2015 and the difference of 0.6% regarding the fruit collected



Figre 2. Chromatogram of Silybi mariani fructus (2015). 1 - silychristin, 2 - silydianin, 3 - silybin A, B, 4 - isosilybin A, B.

Table 1. Fractions of silymarin complex (g.kg⁻¹) in Silybi mariani fructus, 2015 (n = 4).

Silymarin components	Mean ± SD	Median
Silychristin	$3.18\pm0.06^{\circ}$	3.18
Silydianin	$0.91 \pm 0.01^{ m b}$	0.90
Silybin A	$3.06 \pm 0.06^{\circ}$	3.07
Silybin B	7.04 ± 0.07^{d}	7.07
Isosilybin A + B	1.09 ± 0.05^{e}	1.10
Summary	$15.28 \pm 0.06^{\text{A}}$	15.27

Different indices after the numerical values indicate significant differences at the level of P < 0.05. The indices ^{a, b, c, d, e} represent a statistically significant difference between the individual components of the silymarin complex and ^A indicates a significant difference in content of silymarin compared to the content in 2016.

Table 2. Fractions of silymarin complex $(g.kg^{-1})$ in Silybi mariani fructus, 2016 (n = 4).

·	· · · · · · · · · · · · · · · · · · ·	
Silymarin components	Mean ± SD	Median
Silychristin	$4.03 \pm 0.24^{\circ}$	3.97
Silydianin	$1.76 \pm 0.14^{\rm b}$	1.78
Silybin A	2.96 ± 0.15ª	2.99
Silybin B	5.92 ± 0.08°	5.92
Isosilybin A + B	1.98 ± 0.05^{d}	2.00
Summary	$16.65 \pm 0.09^{\text{B}}$	16.66

Different indices after the numerical values indicate significant differences at the level of P < 0.05. The indices ^{a, b, c, d} represent a statistically significant difference between the individual components of the silymarin complex, and ^B indicates a significant difference in content of silymarin compared to the content in 2015.

in 2016. However, the whole process of analysis is timeconsuming. Nevertheless, calibration models are currently being developed for highly efficient and fast determination methods to substitute the HPLC method (Ashie et al., 2021). A promising alternative is a near-infrared (NIR) spectroscopy, a fast and non-destructive method for the analysis of samples without the need of sample pretreatment (Vagnerova et al., 2016). This NIR technique gives information about structural and physical qualities of materials based on the radiation transmittance or reflectance at wavelengths in various ranges (Rodriguez-Saona et al., 2000). The proposed method offers a promising approach to the determination of the quality and quantity of active ingredients for its rapid and nonpolluting properties and low costs (Ashie et al., 2021). Using NIR technique, Vagnerova et al. (2016) found out that the varieties of milk thistle (Silyb and Mirel) have different ratio

of the main silymarin complex components. They also proved that the calibration model of studied varieties can be used to identify an unknown sample. This model is able to classify these varieties. Drouet et al. (2019) used ultrasound extraction to determine the content of the silymarin complex, which was at least 1.80 g.kg⁻¹, and a liquid extraction to quantify the flavonolignans. They observed that silvbin B presented the highest representation (7.52-1.29 g.kg⁻¹), followed by silydianin (4.21-0.40 g.kg⁻¹), isosilybin A (2.49-0.45 g.kg⁻¹), silychristin (1.52–0.01 g.kg⁻¹) and silybin A (1.09–0.01 g.kg⁻¹). In another study, Ghafor et al. (2014) analysed the amount of flavonolignans and determined that the highest content within the silymarin complex was reached by silybin A. In all our measurements, we recorded the predominance of silybin B. Wallace et al. (2005) compared the yield of silymarin in the extraction with ethanol boiling at 78.3 °C and ethanol heated to 60 °C. They found out that the average value of silymarin in the fruit in the extraction with boiling ethanol was 5.0 $mg.g^{-1} = 5.0 g.kg^{-1}$, while a 60 °C ethanol caused an increase in yield by 1.7 times. From this study, we can conclude that the preparation of mash or decoction of Silybi mariani fructus can degrade the whole silymarin complex and, at the same time, reduce the effects of the ingredients. The most studied substance from silymarin complex is silybin, which exists in the form of two stereoisomeric compounds: silybin A and silybin B. Poppe and Petersen (2016) presented in their study that the content of these components represents 10%-20% of the silymarin content, while isosilybin B represents only about 5% of its content. According to another study, using the same assay procedure as we used in our study, the silybin A content ranged from 0.44 g.kg⁻¹ to 11.77 g.kg⁻¹, while the silychristin content varied from 2.05 g.kg⁻¹ to 15.11 g.kg⁻¹. The average content of isosilybin A was 4.70 g.kg⁻¹ and 3.67 g.kg⁻¹ (Arampatzis et al., 2018). Khan et al. (2015) reported that the concentrations of various silymarin components strongly depend on growth conditions, and stress conditions have a strong impact on its biosynthesis. According to the European Pharmacopoeia, which sets the minimum content of silymarin in the dried drug to 1.5%, we can state that both samples meet the requirements of Pharmacopoeia (1.5% in 2015 and 1.7% in 2016).

ACKNOWLEDGEMENTS

We would like to thank Ing. Lubomír Kobida for the consultation and chemical analysis. This study was elaborated thanks to the support of the Operational Programme of Integrated Infrastructure for the Project: Long-term Strategic Research of Prevention, Intervention and Mechanisms of Obesity and Its Comorbidities, IMTS: 313011V344, co-financed by the European Regional Development Fund, and project VEGA 1/0749/21.

References

- Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytotherapy Research 2010;24:1423-1432.
- [2] Abouzid SF, Chen SN, Mcalpine JB, Friesen JB, Pauli GF. Silybum marianum pericarp yields enhanced silymarin products. J. Fitote. 2016;56:136-143.
- [3] Alhadidi Q, Ahmed ZA, Numan IT, Hussain SAR. Dose-dependent anti-inflammatory effect of silymarin in experimental animal model of chronic inflammation. Afr. J. Pharm. Pharmacol. 2009;3:242-247.
- [4] Andrzejewska J, Sadowska K, Mielcarek S. Effect of sowing date and rate on the yield and flavonolignan content of the fruits of milk thistle (Silybum marianum L. Gaertn.) grown on light soil in a moderate climate. J. Ind. Crop. 2011;33:462-468.
- [5] Arampatzis AD, Karkanis CA, Tsiropoulos GN. Siymarin content and antioxidant activity of seeds of wild Silybum marianum populations growing in Greece. J AAB. 2018;174.
- [6] Ashie A, Lei H, Han B, Xiong M, Yan H. Fast determination of free components in milk thistle extract with a hand-held NIR spectrometer and chemometrics tools. Infra Phys Tech. 2021;113:103629.
- [7] Block KI, Gyllenhaal C, Lowe L, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol. 2015;35:276-304.
- [8] Borah A, Paul R, Choudhury S, et al. Neuroprotective potential of silymarin against CNS disorders: Insight into the pathways and molecular mechanisms of action. CNS. 2013;19:847-853.
- [9] Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010;29:447-463.
- [10] Drouet S, Leclerc AE, Garros L. A Green Ultrasound-Assisted Extraction Optimization of the Natural Antioxidant and Anti-Aging Flavonolignans from Milk Thistle Silybum marianum (L.) Gaertn. Fruits for Cosmetic Applications. Antioxidants. 2019;8:304.
- [11] Elateeq AA, Sun Y, Nxumalo W, Gabr MMA. Biotechnological production of silymarin in Silybum marianum L.: A review. J. BCAB. 2020;29:101775.
- [12] European Pharmacopoeia: 10th Edition. Strasbourg: EDQM Publications; 2020.
- [13] Ghafor Y, Mohammad NN, Salh DM. Extraction and Determination of Chemical Ingredients from Stems of Silybum Marianum. CMR. 2014;6:26-32.
- [14] Ghorbani A. Studies on pharmaceutical ethnobotany in the region of Turkmen Sahra, north of Iran: (Part 1): General results. J Ethpharm. 2005;102:58-68.
- [15] Giuliani C, Tani C, Bini LM, Fico G, Colombo R, Martinelli T. Localization of phenolic compounds in the fruits of *Silybum marianum* characterized by different silymarin chemotype and altered colour. J. Fitote. 2018:210 -218.
- [16] Jedlinszki N, Kálomista I, Galbács G, Csupor D. Silybum marianum (milk thistle) products in Wilson's disease: a treatment or a threat? J. Her. Med. 2016;6:157-159.

- [17] Karkanis A, Bilalis D, Efthimiadou A. Cultivation of milk thistle (Silybum marianum L. Gaertn.), a medicinal weed. J Ind Crop. 2011;1:825-830.
- [18] Khan AM, Abbasi HB, Shah AN, Yücesan B, Ali H. Analysis of metabolic variations throughout growth a nd development of adventitious roots in *Silybum marianum* L. (Milk thistle), a medicinal plant. PCTOC. 2015;123:501-510.
- [19] Li D, Hu J, Wang T, et al. Silymarin attenuates cigarette smoke extract-induced inflammation via simultaneous inhibition of autophagy and ERK/p38 MAPK pathway in human bronchial epithelial cells. Sci rep. 2016;6.
- [20] Li L, Zeng J, Gao Y, He D. Targeting silibinin in the antiproliferative pathway. Expert Opinion on Investigational Drugs. 2010;19:243-255.
- [21] Lucini L, Pellizzonii M, Pellegrino R, Molinari GP, Colla G. Phytochemical constituents and *in vitro* radical scavenging activity of different *Aloe* species. J Food Chem. 2015;170:501-507.
- [22] Marmouzi I, Bouyahaya A, Ezzat MS, Jemli EM, Kharbach M. The food plant Silybum marianum (L.) Gaertn.: Phytochemistry, Ethnopharmacology and clinical evidence. J Ethpharm. 2021;265:113303.
- [23] Mei L, Wang L, Li Q, Yu J, Xu X. Comparison of acid degumming and enzymatic degumming process for Silybum marianum seed oil. J. Sci. Food Agric. 2013;93:2822-2828.
- [24] Mirdeilami ZS, Barani H, Mazandarani M, Heshmati AG. Ethnopharmacological Survey of Medicinal Plantsin Maraveh Tappeh Region, NorthofIran. J.P.P. 2011;2:325-336.
- [25] Nagy M, Mučaji P, Grančai D. Farmakognózia. Biologicky aktívne rastlinné metabolity a ich zdroje. Bratislava: Herba; 2015.
- [26] Pendry BA, Kemp V, Hughes MJ, et al. Silymarin content in Silybum marianum extracts as a biomarker for the quality of commercial tinctures. J Herb Med. 2017;10:31-36.
- [27] Polyak JS, Ferenci P, Pawlotsky MJ. Hepatoprotective and Antiviral Functions of Silymarin Components in HCV Infection. PMC. 2014;57:1262-1271.
- [28] Poppe L, Peretsen M. Variation in the flavonolignan composition of fruits from different Silybum marianum chemotypes and suspension cultures derived thereform. J Phyto. 2016;131:68-75.
- [29] Qin N, Jia C, Xu J, Li D et al. New amides from seeds of *Silybum marianum* with potential antioxidant and antidiabetic activities. J. Fitot. 2017;119:83-89.
- [30] Ražná K, Hlavačková L, Bežo M et al. Application of the RAPD and miRNA markers in the genotyping of *Silybum marianum* (L.) Gaertn. Acta fytotechn zootechn. 2015;18:83-89.
- [31] Rodriguez-Saona EL, Fry SF, Calvey ME. Use of Fourier Transform Near-Infrared Reflectance Spectroscopy for Rapid Quantification of Castor Bean Meal in a Selection of Flour-Based Products. J. Agric. Food. Chem. 2000;48:5169-5177.
- [32] Singh RP, Tyagi AK Zhao J, Agarwal R. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcin. 2002;23:499-510.
- [33] Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R.

Evaluation of variability of silymarin complex in Silybi mariani fructus harvested during two ...

Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Pros. 2002;53:211-217.

- [34] Vagnerova L, Bradacova M, Pluhackova H. The Determination of Contained Compounds in Milk Thistle (*Silybum marianum* L. (Gaertn.)). Mendel Net. 2016;23:168-172.
- [35] Wallace SN, Carrier DJ, Clausen EC. Batch solvent extraction of flavanolignans from milk thistle (*Silybum marianum* L. Gaertner). Phytochem. Anal. 2005;16:7-16.
- [36] Wianowska D, Wiśniewski M. Simplified Procedure of Silymarin Extraction from Silybum marianum L. Gaertner. J. Chrom. Sci. 2015;53:366-372.

EUROPEAN PHARMACEUTICAL JOURNAL



Antimicrobial activity and cytotoxicity of transition metal carboxylates derived from agaric acid

Original Paper

Habala L.¹[™], Pašková L.², Bilková A.², Bilka F.², Oboňová B.¹, Valentová J.¹

¹Department of Chemical Theory of Drugs, Faculty of Pharmacy, Comenius University in Bratislava, Kalinčiakova 8, 832 32 Bratislava, Slovakia ²Department of Cellular and Molecular Biology of Drugs, Faculty of Pharmacy, Comenius University in Bratislava, Kalinčiakova 8, 832 32 Bratislava, Slovakia

Received 13 November, 2020, accepted 1 March, 2021

Abstract Carboxylato-type transition metal complexes with agaric acid, a bioactive natural compound derived from citric acid, were prepared, and tested *in vitro* for their antimicrobial activity and cytotoxicity. The products as well as agaric acid itself are amphiphilic compounds containing a hydrophilic head (citric acid moiety) and a hydrophobic tail (non-polar alkyl chain). The putative composition of the carboxylates was assigned on grounds of elemental analysis, infrared (IR) and high-resolution mass spectra (HR-MS), as well as in analogy with known complexes containing the citrate moiety. The metal carboxylates showed interesting activity in several microbial strains, especially against *S. aureus* (vanadium complex; MIC = 0.05 mg/ml). They were also tested for their cytotoxic activity in hepatocytes, the highest activity having been found in the copper(II) and manganese(II) complexes. Further research based on these preliminary results is needed in order to evaluate the influence of parameters like stability of the metal complexes in solution on the bioactivity of the complexes.

Keywords Bioinorganic chemistry – metallodrugs – agaric acid – anticancer – antimicrobial – amphiphilic compounds

INTRODUCTION

Metallodrugs (metallopharmaceuticals) are pharmacologically active substances containing metal atoms, which are essential for their biological activity. They exhibit a number of bioactivities, such as anticancer (Galanski et al., 2003; Hanif and Hartinger, 2018; Johnson et al., 2021), antimicrobial (Regiel-Futyra et al., 2017; Lemire et al., 2013), antiviral (de Paiva et al., 2020), and enzyme inhibitory activities (Kilpin and Dyson, 2013; Habala et al., 2018; Lu and Zhu, 2014). Metallodrugs offer several advantageous features over purely organic compounds due to specific characteristics of coordination compounds. Their bioactivity is influenced by the type of central atom, its oxidation and coordination number, charge of the complex, coordination geometry, type and number of the ligands, and so forth (Ndagi et al., 2017; Frezza et al., 2010).

Agaric acid (agaricin, α -hexadecylcitric acid, 2-hydroxy-1,2,3nonadecanetricarboxylic acid) is a natural compound related to citric acid, substituted at C-4 with a hexadecyl chain (Figure 1). Occasionally, however, the term agaric (agaricin) has been used to describe concentrated or dry extracts from the corresponding fungi, so the usage may be somewhat confusing. It occurs in various wood-decay fungi species. It was initially isolated from the fungus Fomitopsis officinalis but can be found in various other species as well, such as Polyporus officinalis and Polyporus igniarius (Stamets, 2006). Fomitopsis officinalis (synonyms: Laricifornes officinalis, Agaricum officinale) is known also under the common name agarikon. It occurs in temperate regions of the world, although it has recently become very rare in Europe and in Asia. It was first described in antiquity by the Greek physician Dioscorides. The fungus has been used for centuries in traditional medicine, especially in the treatment of tuberculosis and pneumonia (Stamets, 2006). It is sometimes named fly agaric due to its traditional use as insecticide against flies. The mushroom is considered poisonous, though the effects are not severe.

Agaricin has been used in traditional medicine in the form of extracts from *Fomitopsis officinalis* in varying degrees of purity. It has a pronounced anhidrotic effect and can be

^{*} E-mail: habala@fpharm.uniba.sk

³ Open Access. © 2021 European Pharmaceutical Journal, published by Sciendo. CC) BY-NC-ND This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Antimicrobial activity and cytotoxicity of transition metal carboxylates derived from agaric acid



Figure 1. Chemical structure of agaric acid.

used in hyperhidrosis due to its parasympatholytic and anticholinergic activity. It has also been used topically as an anti-inflammatory agent and in the treatment of wounds. Its pharmacological utility was recognized early on, for example, the usefulness of 'white agaric' against excessive perspiration, as reported in 1831 in the journal Lancet (Burdach, 1831). Anticancer activity of agaric acid was mentioned in 1967 (Ciaccio et al., 1967). Despite its interesting pharmacological effects and long-time use in traditional medicine, the available data concerning its bioactivity is limited.

Agaric acid is a highly active inhibitor of fatty acid synthesis in mitochondria, acting by inhibition of the enzyme aconitase (Carrano and Malone, 1967). The mechanism of action is not fully understood but stems most likely from the analogy with citrate, for example, it inhibits citrate uptake in mitochondria (Chávez et al., 1978). Agaric acid is highly inhibitory against malic and α -glycerophosphate dehydrogenases at ~3.10⁻ ⁵ M and it also inhibits the growth of the nonpathogenic trypanosomatid Crithidia fasciculata used as a model for the pathogenic representatives of the Trypanosoma genus (Bacchi et al., 1969). Furthermore, it inhibits ADPstimulated respiration. The compound functions as inducer of mitochondrial permeability transition, causing efflux of Ca²⁺, collapse of transmembrane potential and mitochondrial swelling, probably by binding to mitochondrial ADP/ATP carrier (adenine nucleotide translocase, ANT) (García et al., 2005). The multiple negative charge of the citric moiety seems to be instrumental in this activity, along with the insertion of the alkyl chain into the hydrophobic phase of the membrane. Agaric acid is an amphiphilic-type compound as it contains a hydrophilic head (citric acid moiety) as well as a hydrophobic tail (non-polar alkyl chain). Amphiphilic compounds are a category of substances with specific biological activity. When equipped with suitable donor atoms, they can also act as ligands in metal complexes (Schattschneider et al., 2019). The hydrophobic moiety in the resulting complexes can interact with hydrophobic domains of DNA and proteins as well as with lipid membranes, whereas the central metal ion possesses Lewis acid character and thus can form coordination bonds with suitable donor atoms. Furthermore, it imparts redox properties on such complexes. Aggregation and selfassembly of metallosurfactants leads to metallomicelles.

At physiological pH, all three carboxylic groups of agaric acid can dissociate and are available for complexation, along with the hydroxyl group. However, almost no such metal complexes have been reported so far, except for the platinum complex of agaric acid and 1,2-cyclohexanediammine, whose preparation and anticancer activity in animal model was described (Bitha et al., 1986).

Agaric acid (denoted in this study as ligand L or as compound **8**) is a biologically active compound whose pharmacological potential remains largely unexplored. The aim of the presented study was to investigate the influence of complexation with various transition metals on the bioactivity of agaric acid. To this end, transition metal carboxylates of agaric acid with Cu, Ni, V, Co, La, Fe, and Mn were prepared. Here, we present the results of the *in vitro* measurements of their antimicrobial activities and of cytotoxicity in hepatocytes.

MATERIALS AND METHODS

General

The chemicals used in the syntheses were purchased from Sigma-Aldrich and are of analytical grade. They were used without further purification. Double distilled water was employed as reaction medium. Infrared (IR) spectra were measured with the help of the ATR (attenuated total reflectance) technique on a Nicolet 6700 FT-IR spectrometer from Thermo Scientific (Waltham, MA, USA) in the 600-4000 cm⁻¹ range. Elemental analysis was conducted using a Flash2000 instrument from Thermo Scientific (Waltham, MA, USA). High-resolution mass spectra (HR-MS) were recorded on Thermo Scientific[™] LTQ Orbitrap XLTM Hybrid Ion Trap-Orbitrap Mass Spectrometer (Thermo Scientific, Waltham, MA, USA). The instrument was used in full-scan mode (m/z range 100–700). The samples were dissolved in HPLC-grade methanol (conc. 2 ppm) and injected directly into the mass spectrometer. Electrospray (ESI) ion source was used to produce the ions. The conductivity measurements of solutions of the metal carboxylates were carried out in 1 mM dimethyl sulfoxide (DMSO) solutions by means of the conductivity benchtop meter inoLab Cond 7110 (Xylem Analytics, Weilheim, Germany).

General procedure for the synthesis of metal carboxylates

The metal complexes were prepared according to the modified procedures from (Abrahamson et al., 1994; Deng and

Zhou, 2009). Agaric acid (0.417 g, 1.0 mmol) was suspended in 70 ml of water. The mixture was stirred and heated almost to boiling temperature. Subsequently, a solution of NaOH (2.0 or 3.0 mmol, depending on the charge of the metal cation) in 30 ml of water was added. The heating was continued until complete dissolution of the solid. To the resulting clear colourless solution was added dropwise the aqueous solution of the respective metal salt (1 mmol). The following metal salts (as hydrates) were used: CuCl₂·2H₂O, MnCl₂·2H₂O, NiCl₂·6H₂O, CoCl₂·6H₂O, FeCl₂·6H₂O, La(NO₂)₂·6H₂O, VOSO₄·5H₂O. After a short time, coloured precipitate started to form. The reaction mixture was stirred for 3 hours at room temperature. The resulting solid product was separated by filtration, washed successively with water and methanol, and dried in vacuum for several days to yield the product as variously coloured powders.

Antimicrobial activity testing

Antimicrobial activities of metal complexes and of the ligand were evaluated *in vitro* and expressed as the minimum inhibitory concentration (MIC). The standard broth dilution method (Lukáč et al., 2010) was employed in the determination. The following strains of Gram-positive, Gram-negative bacteria and a yeast pathogen were selected for the investigation: *Staphylococcus aureus* CNCTC Mau 29/58, *Escherichia coli* CNCTC 377/79 and *Candida albicans* CCM 8186, respectively. All the bacterial strains were obtained from Czech National Collection of Type Cultures (Prague, Czech Republic); yeast was purchased from Czech Collection of Microorganisms (Brno, Czech Republic).

Evaluation of cytotoxicity in HepG2 cells

HepG2 cells (ATCC HB-8065) were routinely cultured in a humidified atmosphere of 5% CO₂ at 37°C in Dulbecco's Modified Eagle Medium (DMEM) containing 10% Fetal Bovine Serum (FBS) and 0.2% (v/v) of penicillin/streptomycin solution. Complete medium was replaced every 2 to 3 days. The cultivation was carried out in 100 mm dishes. The cell count for a passage was 10 to 25. Cells were trypsinized to detach, then centrifuged, resuspended, seeded at 70% confluency and grown in 24-well culture plates for 24 h. Afterwards, the cells were incubated with rising inhibitor concentrations (0-75 µg/ml) for 24 h. Inhibitors were dissolved in DMSO. The concentration of vehiculum did not exceed 0.75% (v/v) (Miret et al., 2006). At the end of the incubation period, the cell proliferation was appraised using Janus Green B assay as described by Raspotnig et al. (Raspotnig et al., 1999). Briefly, the culture medium was detached from the cell layers by vacuum aspiration and the cell layers were fixed for 30 min in ethanol (50%), with subsequent vacuum aspiration of the fixative. Finally, the fixed cell layers were stained for 3 min with a 0.2% solution of Janus green B in Phosphate-Buffered Saline (PBS) (pH 7.1–7.2) at room temperature. After immediate removal of the stain using a vacuum aspirator, the whole plate was washed twice in cold tap water and eluted from cell layers by the addition of a 0.5 ml of 0.5 M HCl. The plate was analysed with a microplate reader (Biotec 3550-UV) against blanks of 0.5 M HCl at 595 nm. The cell count was determined using the calibration curve, which represents the dependency of A595 on HepG2 cell density. Each experiment was conducted threefold in duplicates.

RESULTS AND DISCUSSION

Synthesis and characterization of the metal complexes

All the metal carboxylates were prepared in good yields. The synthesis was accomplished in aqueous solution from the sodium salt of agaric acid prepared *in situ* and corresponding metal salts. The products were powders of various colours, stable in air. The solubility of the resulting metal carboxylates in common solvents was low in all cases. They were moderately soluble in DMSO and DMF (dimethyl formamide), and to some extent, also in alcohols, especially at elevated temperature. The complexes did not melt within the temperature range used. The syntheses are summarized in Table 1, along with the compositions of the metal carboxylates as obtained by elemental analysis and molar conductivities of their DMSO solutions.

The values of electric conductivity in the DMSO solutions (Table 1) suggest their non-ionic nature (Ali et al., 2013). The results of elemental analysis support the metal/ligand ratio 1:1, with varying number of water molecules present in the solid phase (2 or 3). The metal complexes were further investigated by infrared spectroscopy and high-resolution mass spectroscopy. The selected results of both types of spectroscopic measurements can be found in Table 2.

In the infrared spectra, bands corresponding to the vibrations of carboxyl groups (C=O) can be seen at 1539-1590 cm⁻¹ (asymmetric stretching vibration) and 1394-1440 cm⁻¹ (symmetric vibration). In the spectrum of pure agaric acid (the ligand), the band of the protonated carboxyl group appears at 1691 cm⁻¹. The relatively small difference $v_{ac} - v_{c}$ (around 100-200 cm⁻¹) indicates the presence of coordinated carboxylate groups bonded to the metal in a covalent, bidentate fashion. The generally much higher intensity of the v_{x} (COO⁻) compared to the symmetric vibration band is a sign of coordinative (non-ionic) nature of the carboxylates (Palacios et al., 2004). The very low value of Δv (COO⁻) for iron(III) caboxylate (99 cm⁻¹) may be indicative for chelating bridging type of coordination in this complex. In the spectra of the carboxylates with bivalent metals, a residual carboxyl group (apparently protonated) can be seen at 1703-1705 cm⁻¹, whereas in the case of the trivalent metals (Fe, La) it is absent. The broad band around 3300 cm⁻¹ can be ascribed to the stretching vibrations of the hydroxyl group of the citrate moiety and the water molecules. The intense signal caused

Antimicrobial activity and cytotoxicity of transition metal carboxylates derived from agaric acid

Comp. Nr.	Starting metal salt	Yield	Colour	Molar conductivity	Assumed composition	Eleme analysis	ental theor.	Elem analys	ental is exp.
		%		μS.mol-1.cm2		% C	% H	% C	%H
1	CoCl ₂ ·6H ₂ O	96	pink	9	Co(L-2H)(2H ₂ O)	51.84	8.31	51.70	8.55
2	CuCl ₂ ·2H ₂ O	75	light blue	3	Cu(L-2H)(2H ₂ O)	51.44	8.25	51.17	8.03
3	NiCl ₂ ·6H ₂ O	82	light-green	10	Ni(L-2H)(3H ₂ O)	50.17	8.43	50.19	8.46
4	La(NO ₃) ₃ ·6H ₂ O	87	white	2	La(L-3H)(2H ₂ O)	44.90	7.02	44.91	7.19
5	VOSO ₄ ·5H ₂ O	84	grey-blue	11	VO(L-2H)(3H ₂ O)	49.34	8.28	49.30	8.03
6	FeCl ₃ ·6H ₂ O	86	light-brown	3	Fe(L-3H)(3H ₂ O)	50.46	8.28	50.50	7.95
7	MnCl ₂ ·2H ₂ O	95	brownish- white	5	Mn(L-2H)(2H ₂ O)	52.27	8.37	52.79	8.30

Table 1. The prepared metal carboxylates.

Table 2. Characteristic signals in IR and HR-MS spectra.

Substance	<i>v_{as}</i> (COO ⁻) ^a	ν _s (COO⁻) ^ь	Δν(COO ⁻) ^c	ν(C=O)	<i>m/z</i> theor. ^d	<i>m/z</i> found
1 (Co)	1590	1394	196	1704	472.1872	472.1875
2 (Cu)	1567	1417	150	1704	476.1836	476.1839
3 (Ni)	1575	1417	158	1704	471.1893	471.1899
4 (La)	1558	1403	155		(552.1603)	
5 (V)	1563	1423	140	1705	480.1928	480.1932
6 (Fe)	1539	1440	99		468.1811	468.1816
7 (Mn)	1569	1409	160	1703	(468.1920)	
8 (L)				1691	415.2696	415.2701

^a v_{a} (COO⁻): asymmetric stretching vibration of the carboxyl; ^b v_{a} (COO⁻): symmetric stretching vibration of the carboxyl; ^c Δv (COO⁻) = v_{a} (COO⁻) - v_{a} (COO⁻); ^d the composition assigned to pseudomolecular ion was in all cases [M(L-nH)]⁻, where n = 3–4, depending on the charge of the metal cation

by asymmetric vibrations of the COO⁻ groups overlaps with coordinated water deformation mode expected at approx. 1640 cm⁻¹. Strong and sharp absorption bands corresponding to v(CH, CH₂) vibrations are found at approximately 2850 and 2900 cm⁻¹, those of δ (CH, CH₂) around 1230–1300 cm⁻¹. In the spectrum of the vanadium carboxylate, bands attributed to the vibrations of the V=O group can be seen as well: v_s (V=O) = 988 cm⁻¹, v_{as} (V=O) = 859 cm⁻¹. Generally, many signals in the spectra of metal carboxylates are shifted towards lower frequencies compared to those of free agaric acid, pointing to changes in vibrational status upon complexation to the respective metal.

The high-resolution mass spectrometry (HR-MS) with ESI ion source provides precise m/z values, enabling in this way the assignment of pseudomolecular ions for the compounds. The attempted ionization in positive mode did not produce molecular ions of the compounds, therefore, we had to resort to mass-spectrometric (MS) measurements in the negative mode. In most cases, we were able to find the pseudomolecular ion with the composition [M(L-3H)]⁻ or [M(L-4H)]⁻, except for

the carboxylates of lanthanum and manganese. This can be attributed to the instability of these metal complexes in the mass spectrometer. The results support the metal/ligand ratio 1:1.

As an example, the HR-MS spectrum of the carboxylate of vanadyl is given in Figure 2. The signal of the pseudomolecular ion of the vanadium complex can be seen at m/z 480.1932. The free ligand (anion of agaric acid), originating from the dissociation of the complex, appears at m/z 415.2699.

Regarding the structures of analogous metal complexes with citric acid, it can be concluded that the structures of the prepared complexes might in some cases be dimeric or oligomeric, the great majority of them conforming to 1:1 metal/ligand ratio, for example, Zabiszak et al. (2018), Boghaei and Najafpour (2007), Huta et al. (2012), Field et al. (1974) and Zhou et al. (1999). The exact composition of these citrate complexes is often dependent on the pH of the reaction solution, for example, in the cobalt(II) complexes with citrate reported in Zhou et al. (2005). The coordination environment of cobalt in these complexes is



Figure 2. HR-MS spectrum of the vanadium carboxylate (5).

octahedral and the ligand is tridentate, binding through two carboxylates and the hydroxyl group. This type of coordination seems to be prevalent also in complexes with several other metals. With the copper(II) complex, a variety of structures seem possible as well (Boghaei and Najafpour, 2007; Drzewiecka et al., 2007; Mastropaolo et al., 1976). The presence of one or several charge-compensating counter-ions (like Na⁺) is also possible, as in nickel(II) citrate (Baker et al., 1983) or in iron(III) citrate (Pierre and Gautier-Luneau, 2000; Vukosav et al., 2012). The ionic nature of any of the corresponding complexes with agaric acid can be fairly ruled out on the grounds of the results of electrical conductivity measurement (low values). The lanthanum complex with citric acid (Baggio and Perec, 2004) exhibits the composition [La(Hcit)(H₂O)], and a polymeric structure, which could also fit well with the structure of the agaric acid analog, considering the $(v_{as} - v_s)$ value for the carboxylate in the IR spectra of the complex. Even if the analogy between complexes of citric and agaric acids might be useful, there are limits to this approach due to the steric requirements of the bulky alkyl substituent in agaric acid. To definitely establish the constitution and geometric arrangement of the metal carboxylates, further research is needed. The most straightforward method, X-ray single-crystal analysis, was not feasible as yet, due to difficulties with the preparation of single crystals of the complexes.

To sum up, the molar ratio metal/ligand 1:1 can be attributed to the prepared complexes. They are of non-ionic nature, most likely with hexacoordinate central atoms surrounded by the partly deprotonated agaric acid and several aqua ligands. They conform to the relative composition $M(L-mH)(H_2O)_n$ where m, n = 2 or 3.

Bioactivity

The prepared complexes along with the ligand were tested for their antimicrobial activity. Two bacterial strains (*S. aureus* and *E. coli*) and a yeast strain (*C. albicans*) were used. The results are summarized in Table 3. The best results were achieved with the vanadium carboxylate **5** in *S. aureus* (0.05 mg/ml). Interestingly, the activities of the same vanadium complex in *C. albicans* and *E. coli* were low. The results in other microbial strains were only inferior. Also, the antimicrobial activity of the copper complex, where the highest effect could be expected, was only mediocre. The activity of the ligand was in the same range as activity of the least active carboxylates.

Antimicrobial activity and cytotoxicity of transition metal carboxylates derived from agaric acid



Figure 3. Cell viability for the investigated substances in the concentration range $0-75 \mu g/ml$.

Cubatanaa		MIC (mg/ml)			
Nr.	Metal	S. aureus	E. coli	C. albicans	
1	Со	0.22	0.44	0.88	
2	Cu	0.44	1.75	0.44	
3	Ni	>3.5	1.75	0.88	
4	La	1.75	1.75	1.75	
5	V	0.05	3.5	0.88	
6	Fe	3.5	0.88	0.44	
7	Mn	3.5	3.5	0.44	
8	(ligand)	1.75	3.5	0.88	

Table 3. Antimicrobial activity of metal carboxylates and the ligand (MIC = minimum inhibitory concentration).

The activities of the free metal ions can be appraised from the literature (Harrison et al., 2004; Nies, 1999)

To estimate the anticancer properties of the considered compounds, cytotoxicity in the human liver cancer cell line HepG2 was evaluated. HepG2 is an immortal cell line derived from hepatocellular carcinoma. It represents an *in vitro* model system for investigation of polarized human hepatocytes. The cell viability (percentage of cell survival) was determined in the concentration range 0–75 µg/ml (25 µg/ml step). The results are shown in Figure 3.

All the investigated complexes appear to be cytotoxic at the studied concentrations. The ligand itself (8) also exhibited comparatively high activity (21.5 % at 50 μ g/ml). The activities of the free metal ions can be appraised from the literature (Borenfreund and Puerner, 1986).

The highest cytotoxicity was exercised at 50 $\mu g/ml$ by the copper complex ${\bf 2}$ and the manganese complex ${\bf 7}$ (13.3

and 14.1 µg/ml, respectively). Interestingly, at 50 µg/ml the activities of all the complexes except these two were lower than the activity of the ligand but the picture changes at 75 µg/ml, where all the complexes except those of La and V score better than the pure ligand. Thus, the formation of metal carboxylates seems to improve upon the activity of the ligand (agaric acid), except in the case of the vanadium complex and even more so in the case of the lanthanum carboxylate. It is difficult to give a proper explanation for this synergic effect but binding of agaric acid to the metal might possibly facilitate the crossing of the cell membrane and thus accumulation of the metal in the cell. Similar improvement of cell membrane passage was observed in the amphiphilic Ru(II) complex reported in Siewert et al. (2017). Charged ruthenium species generally exhibit low cellular uptake (Alessio, 2016), yet this was radically improved upon incorporation of a C₁₂ alkyl chain into the aforementioned ruthenium complex. Synergic effect of Cu(II)/Fe(III) complexation of non-ionic amphiphilic Schiff bases on antimicrobial activities was shown by Negm and Zaki (2008). It can be concluded that the donor atoms represent a highly hydrophilic area within the ligand, thus the lipophilicity of the complex molecule increases upon coordination to metal ions (decreasing the electron density of the moiety). This might lead to increased adsorption on the lipid-containing cell walls and affect the permeability of the membranes, resulting in more facile passage through the cell membrane of the microbes (Negm and Zaki, 2008; Schattschneider et al., 2019).

Another effect exercised by amphiphilic complexes could be improved protein binding, as demonstrated in the cobalt(III) complex carrying two phenanthroline ligands and a hydrophobic tetradecylamine ligand with a high affinity to human serum albumin (HSA) (Kumar et al., 2011). An amphiphilic complex of cobalt(III) carrying a dodecylamine ligand is able to intercalate with its long hydrophobic chain between the base pairs in DNA, as indicated by cyclic voltammetry, spectroscopic methods and DNA viscosity measurements (Nagaraj and Arunachalam, 2014).

CONCLUSIONS

Agaric acid is a natural compound with manifold biological activities. In the course of this work, 7 new compounds, that is, carboxylates of agaric acid with transition metals were prepared. The complexes and the ligand (agaric acid) were tested for their *in vitro* antimicrobial activity against bacteria and yeast, as well as for their cytotoxicity in the hepatocytic cancer cell line HepG2.

Considerable antibacterial activity was found in the vanadium carboxylate, active against *S. aureus*. The majority of the complexes showed marked anticancer *in vitro* activity. The cytotoxicity was highest for the copper and manganese carboxylates.

The results are generally encouraging, especially considering that the expected molecular mass of the carboxylates might be quite high, and the complexes thus exhibit activity at low molar concentrations. The compounds are also interesting because of their amphiphilic nature. Hence, further investigation of these carboxylate complexes would be worthwhile, in particular into their structure and additional bioactivities. Of special interest is the evaluation of the behaviour of the complexes in solution, since they may undergo various changes upon dissolution, such as ligand dissociation and exchange. Based on the available analytical data, the complexes might be oligomeric or polymeric, thus their structure in aqueous solution can differ considerably from the solid-state structure.

ACKNOWLEDGMENTS

This publication was supported by the Scientific Grant Agency of the Slovak Republic, grant VEGA 1/0145/20, and Comenius University grant UK/324/2020.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

References

- Abrahamson HB, Rezvani AB, Brushmiller JG. Photochemical and spectroscopic studies of complexes of iron(II1) with citric acid and other carboxylic acids. Inorg Chim Acta. 1994;226:117–127.
- [2] Alessio E. Thirty years of the drug candidate NAMI-A and the myths in the field of ruthenium anticancer compounds: a personal perspective. Eur J Inorg Chem. 2017;2017:1549–1560.
- [3] Ali I, Wani WA, Saleem K. Empirical formulae to molecular structures of metal complexes by molar conductance. Synth React Inorg Met-Org Chem. 2013;43:1162–1170.
- [4] Bacchi CJ, Ciaccio El, Koren LE. Effects of some antitumor agents on growth and glycolytic enzymes of the flagellate *Crithidia*. J Bacteriol. 1969;98:23–28.
- [5] Baggio R, Perec M. Isolation and characterization of a polymeric lanthanum citrate. Inorg Chem. 2004;43:6965–6968.
- [6] Baker EN, Baker HM, Anderson BF, Reeves RD. Chelation of nickel(II) by citrate. The crystal structure of a nickel-citrate complex, K₂[Ni(C₆H₅O₇)(H₂O)₂]₂. Inorg Chim Acta. 1983;78:281–285.
- [7] Bitha P, Child RG, Hlavka JJ, Lin Y. Platinum complexes of aliphatic tricarboxylic acid. EP0185225A1, Jun 25, 1986
- [8] Boghaei DM, Najafpour MM. Crystal structure of Gua₄[Cu₂(Cit)₂] {Gua = Guanidinium, Cit = Citrate = 2-hydroxo-1,2,3-tricarboxylatopropane}. Anal Sci. 2007;23:23–24.
- [9] Borenfreund E.; Puerner JA. Cytotoxicity of metals, metal-metal and metal-chelator combinations assayed in vitro. Toxicology. 1986;39:121–134.
- [10] Burdach M. Use of the white agaric in night perspirations. The Lancet. 1831;16:316.
- [11] Carrano RA, Malone MH. Pharmacologic study of norcaperatic and agaricic acids. J Pharm Sci. 1967;56:1611–1614.

- [12] Chávez E, Chávez R, Carrasco N. The effect of agaric acid on citrate transport in rat liver mitochondria. Life Sci. 1978;23:1423–1429.
- [13] Ciaccio El, Boxer GE, Devlin TM, Ford RT. Screening data from selected in vitro enzymatic systems I. Standard test compounds from the Cancer Chemotherapy Nation Service Center. Cancer Res. 1967;27:1033–1069.
- [14] Ciaccio El, Boxer GE, Devlin TM, Ford RT. Screening data from selected in vitro enzymatic systems II. Compounds specifically selected for the dehydrogenase inhibition screens. Cancer Res. 1967;27:1070–1104.
- [15] de Paiva REF, Marçal Neto A, Santos IA, Jardim ACG, Corbi PP, Bergamini FRG. What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks. Dalton Trans. 2020;49:16004–16033.
- [16] Deng YF, Zhou ZH. Synthesis and crystal structure of a zinc citrate complex [Zn(H,cit)(H,O)], J Coord Chem. 2009;62:1484–1491.
- [17] Drzewiecka A, Koziol AE, Lowczak M, Lis T. Poly[tetraaquadi- μ_{6} -citrato-tetra-copper(II)]: a redetermination. Acta Cryst. 2007;E63:m2339–m2340.
- [18] Field TB, McCourt JL, McBryde WAE. Composition and stability of iron and copper citrate complexes in aqueous solution. Can J Chem. 1974;52:3119–3124.
- [19] Frezza M, Hindo S, Chen D, Davenport A, Schmitt S, Tomco D, Dou QP. Novel metals and metal complexes as platforms for cancer therapy. Curr Pharm Des. 2010;16:1813–1825.
- [20] Galanski M, Arion VB, Jakupec MA, Keppler BK. Recent developments in the field of tumor-inhibiting metal complexes. Curr Pharm Des. 2003;9:2078–2089.

Antimicrobial activity and cytotoxicity of transition metal carboxylates derived from agaric acid

- [21] García N, Zazueta C, Pavón N, Chávez E. Agaric acid induces mitochondrial permeability transition through its interaction with the adenine nucleotide translocase. Its dependence on membrane fluidity. Mitochondrion. 2005;5:272–281.
- [22] Habala L, Devínsky F, Egger AE. Metal complexes as urease inhibitors. J Coord Chem. 2018;71:907–940.
- [23] Hanif M, Hartinger CG. Anticancer metallodrugs: where is the next cisplatin? Future Med Chem. 2018;10:615–617.
- [24] Harrison JJ, Ceri H, Stremick CA, Turner RJ. Biofilm susceptibility to metal toxicity. Environ Microbiol. 2004;6:1220–1227.
- [25] Huta B, Lensboeur JJ, Lowe AJ, Zubieta J, Doyle RP. Metal-citrate complex uptake and CitMHS transporters: From coordination chemistry to possible vaccine development. Inorg Chim Acta. 2012;393:125–134.
- [26] Johnson A, Northcote-Smith J, Suntharalingam K. Emerging metallopharmaceuticals for the treatment of cancer. Trends Chem. 2021;3:47–58.
- [27] Kilpin KJ, Dyson PJ. Enzyme inhibition by metal complexes: concepts, strategies and applications. Chem Sci. 2013;4:1410– 1419.
- [28] Kumar RS, Paul P, Riyasdeen A, Wagniéres G, van den Bergh H, Akbarsha MA, Arunachalam S. Colloids Surf B Biointerfaces. 2011;86:35–44.
- [29] Lemire JA, Harrison JJ, Turner RJ. Antimicrobial activity of metals: mechanisms, molecular targets and applications. Nat Rev Microbiol. 2013;11:371–384.
- [30] Lu L, Zhu M. Protein tyrosine phosphatase inhibition by metals and metal complexes. Antioxid Redox Signal. 2014;20: 2210– 2224.
- [31] Lukáč M, Lacko I, Bukovský M, Kyselová Z, Karlovská J, Horváth B, Devínsky F. Synthesis and antimicrobial activity of a series of optically active quaternary ammonium salts derived from phenylalanine. Open Chem. 2010;8:194–201.
- [32] Mastropaolo D, Powers DA, Potenza JA, Schugar HJ. Crystal structure and magnetic properties of copper citrate dihydrate, Cu₂C₆H₄O₇·2H₂O. Inorg Chem. 1976;15:1444–1449.
- [33] Miret S, De Groene EM, Klaffke W. Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2. J Biomol Screen. 2006;11:184–193.
- [34] Nagaraj K, Arunachalam S. Synthesis, CMC determination, nucleic acid binding and cytotoxicity of a surfactant-cobalt(iii) complex: Effect of ionic liquid additive. New J Chem. 2014;38:366–375.
- [35] Ndagi U, Mhlongo N, Soliman ME. Metal complexes in cancer therapy – an update from drug design perspective. Drug Des Devel Ther. 2017;11:599–616.
- [36] Negm NA, Zaki MF. Structural and biological behaviors of some nonionic Schiff-base amphiphiles and their Cu(II) and Fe(III) metal complexes. Colloids Surf B Biointerfaces. 2008;64:179–183.
- [37] Nies DH. Microbial heavy-metal resistance. Appl Microbiol Biotechnol. 1999;51:730–750.
- [38] Palacios EG, Juárez-López G, Monhemius AJ. Infrared spectroscopy of metal carboxylates II. Analysis of Fe(III), Ni and Zn carboxylate solutions. Hydrometallurgy. 2004;72:139–148.

- [39] Pierre JL, Gautier-Luneau I. Iron and citric acid: A fuzzy chemistry of ubiquitous biological relevance. BioMetals. 2000;13:91–96.
- [40] Raspotnig G, Fauler G, Jantscher A, Windischhofer W, Schachl K, Leis HJ. Colorimetric determination of cell numbers by Janus green staining. Anal Biochem. 1999;275:74–83.
- [41] Regiel-Futyra A, Dąbrowski JM, Mazuryk O, Śpiewak K, Kyzioł A, Pucelik B, Brindell M, Stochel G. Bioinorganic antimicrobial strategies in the resistance era. Coord Chem Rev. 2017;351:76– 117.
- [42] Schattschneider C, Kettenmann SD, Hinojosa S, Heinrich J, Kulak N. Biological activity of amphiphilic metal complexes. Coord Chem Rev. 2019;385:191–207.
- [43] Siewert B, Langerman M, Hontani Y, Kennis JTM, van Rixel VHS, Limburg B, Siegler MA, Talens Saez V, Kieltyka RE, Bonnet S. Turning on the red phosphorescence of a [Ru(tpy)(bpy)(Cl)]Cl complex by amide substitution: self-aggregation, toxicity, and cellular localization of an emissive ruthenium-based amphiphile. Chem Commun. 2017;53:11126–11129.
- [44] Stamets P. Antiviral activity from medicinal mushrooms. US 2006/0171958 Al, Aug 3, 2006
- [45] Vukosav P, Mlakar M, Tomišić V. Revision of iron (III)-citrate speciation in aqueous solution. Voltammetric and spectrophotometric studies. Analyt Chim Acta. 2012;745:85–91.
- [46] Zabiszak M, Nowak M, Taras-Goslinska K, Kaczmarek MT, Hnatejko Z, Jastrzab R. Carboxyl groups of citric acid in the process of complex formation with bivalent and trivalent metal ions in biological systems. J Inorg Biochem. 2018;182:37–47.
- [47] Zhou ZH, Deng YF, Wan HL. Structural Diversities of Cobalt(II) Coordination Polymers with Citric Acid. Cryst Growth Des. 2005;5:1109–1117.
- [48] Zhou ZH, Zhang H, Jiang YQ, Lin DH, Wan HL, Tsai KR. Complexation between vanadium(V) and citrate: spectroscopic and structural characterization of a dinuclear vanadium(V) complex. Trans Met Chem. 1999;24:605–609.



EUROPEAN PHARMACEUTICAL JOURNAL

Iridoids From Stachys Byzantina K. Koch (Lamb's Ears) And Stachys Germanica L. (Downy Woundwort)

Original Paper

Háznagy-Radnai E.¹, Czigle Sz.^{2,⊠}, Máthé I.¹

¹Institute of Pharmacognosy, Faculty of Pharmacy, University of Szeged, Eötvös 6, H-6720 Szeged, Hungary ²Department of Pharmacognosy and Botany, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, SK-832 32 Bratislava, Slovak Republic ³Institute of Ecology and Botany, Hungarian Academy of Sciences, Alkotmány u. 2-4., H-2163 Vácrátót, Hungary

Received 16 March, 2021, accepted 6 May, 2021

AbstractIridoids are a class of secondary metabolites found in a wide variety of plants. Iridoids are typically found in plants as glycosides,
most often found to glucose. The genus Stachys L. is one of the largest genera of the Lamiaceae family, containing iridoids.
Aim: The aim of this study was the isolation and identification of iridoids from the aerial parts of Stachys byzantina K. Koch and
Stachys germanica L.
Methods: For the isolation and identification of the iridoids, different chromatographic methods (NP-TLC, CPC and RP-HPLC) were
used. The structures were established by one- and two-dimensional NMR and mass spectrometry, also.
Results: Iridoids (aucubin, harpagide, ajugoside and harpagoside) were isolated and identified by combination of different
chromatographic methods from S. byzantina and S. germanica.

Conclusion: Stachys species may also be used as a potential source of iridoids.

Keywords Stachys germanica – Stachys byzantina – iridoids – harpagide – aucubin – ajugoside – harpagoside

INTRODUCTION

The family Lamiaceae consists of approximately 200 genera of 3500 species. The woundwort (Stachys L.) genus consists of 300 species. This is the third-largest relationship group of Labiate plants. It grows everywhere in the world with the exception of Australia, New Zealand and the Arctic regions. The number of species is particularly high in the Mediterranean region, Eastern Europe, Cape Province and Chile. Ten species live in Central Europe. The flowers of these annual or perennial herbs are light purple, dark pink, yellow or white. Some species grow in Hungary, too. S. officinalis L. is found in Europe, so in Hungary as well. S. alpina L. likes shady places, and it is found in fresh hornbeam-beech forests. S. germanica L. also grows in Hungary and Slovakia, and it is quite frequent in dry grasslands and pastures. S. byzantina L. is found as an ornamental plant, and S. grandiflora Stev. ex Willd. and S. macrantha K. Koch are found in botanical gardens. S. sylvatica L. can be found in hilly and mountainous zones along shrubs and forest paths, in moist, leafy forests,

groves, scrubs and by forest springs. It lives on moist and wet clay and adobe soils which are rich in nutrients and have a neutral pH. *S. palustris* L. is widespread in the greater part of Europe, and it is common in Hungary, especially along marshes and bogs. *S. recta* L. is frequent on dry, stony grasses and steppe slopes. *S. annua* L. is found in most of Southern and Central Europe; it is native to Northern Europe; in Hungary, it is an ordinary plant. It can be found in ploughlands and stubble fields, mainly on hard soils (Tomou et al., 2020; Tutin et al., 1972).

Some members of the *Stachys* genus (extracts or their content material) have significant antibacterial, antifungal and antiphlogistic effects, and they can also be useful in anoxia, hepatitis and nephritis. It is proved by literature data that *Stachys* species have long been used in folk medicine for the treatment of genital tumours and cancerous ulcers (Skaltsa et al., 1999, 2001; Tomou et al., 2020).

^{*} E-mail: czigle@fpharm.uniba.sk

³ Open Access. © 2021 European Pharmaceutical Journal, published by Sciendo. CBY-NC-ND This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Stachys species belong to the Lamioideae subfamily, and thus, they contain volatile oils in traces, but they have a great number of other secondary metabolic products, e.g. iridoids. As for their structure, their iridoids usually have 9 C atoms, with an OH group on C5 or C6. They typically contain a methyl or acetyl group on C8, giving C8 a quaternary character. For the most part, these iridoids cannot be detected in UV light, and therefore, a developing reagent is needed to make them visible. Their structure is relatively simple; at the same time, they are very sensitive to acids and enzymes, the presence of which leads to the decomposition of the compound (El-Naggar & Beal, 1980; Kobzar, 1986; Derkach et al., 1987; Jeker et al., 1989; Calis et al., 1991; Boros & Stermitz, 1990, 1991; Isamukhamedova & Pulatova, 1992; Kartev et al., 1994; Miyase et al., 1990; Munoz & Pena, 2001).

The aim of this study was the isolation and identification of iridoids from the aerial parts of *Stachys byzantina* (lamb's ears) and *Stachys germanica* (downy woundwort).

MATERIALS AND METHODS

Stachys germanica was collected at the Medicinal Plant Garden of the Faculty of Pharmacy, Comenius University in Bratislava. Stachys byzantina was gathered at Hungarian biotope and the Botanical Garden, Vácrátót, Hungary. Voucher specimens were deposited in the Institute of Pharmacognosy, University of Szeged, Hungary. The aerial parts of both species were collected at the flowering time, in June. The samples were conserved at -20°C until processing.

Solvents of analytical purity were purchased by Reanal (Budapest, Hungary), those of HPLC purity by Merck (Darmstadt, Germany).

Extraction and isolation of iridoids

S. byzantina and *S. germanica* were rubbed with CaCO₃ and extracted with methanol using ultrasonic shaker and Gerhardt shaker. The total methanolic extract was further purified on aluminium oxide (90 active neutral column 0.063–0.200 mm, Merck, Germany (70–230 mesh ASTM)). Extracts were concentrated under vacuum with a Rotavapor RE (Büchi, Germany) rotary evaporation system. This was dissolved in water, and a liquid-liquid distribution was performed with chloroform. Chlorophyll of all samples was removed by using a polyamide column chromatography.

Purification and isolation of chemical compounds

Silica gel 60 G (mean particle size 15 μ m) (Merck, Germany) was used for vacuum-liquid chromatography (VLC). The concentrated extract was 6 g for *S. byzantina* and 8 g for *S. germanica*. After dissolution in water, VLC fractionation was carried out by using a water pump. Eluents were chloroform:methanol:water [70:10:1 and 10:70:1] and methanol:water [40:10 and 10:40].

The composition of the fractions was checked with thin-layer chromatography (TLC) in each case, and the solvent system was $CHCl_3$:MeOH:H₂O [25:10:1], as a mixture developed in this work, while the developer was the 1% concentrated hydrochloric acid solution of 4-(dimethylamino)benzaldehyde (105°C, 5 min).

The HPLC system (Shimadzu SPD 10 A/10 AV HPLC, Shimadzu Corporation, Japan) consisted of a gradient pump, analytical sampling valve, UV detector and integrator with software. Columns: BST SI-100 10 C-18 (250 mm, Ø 4 mm; Merck, Germany) and LiChrospher RP-18 (250 mm, Ø 5 μ m; Merck, Germany), solvent system: method 1: water:acetonitrile [90:10]; method 2 – eluent: water:acetonitrile [98:2]; gradient program: isocratic; flow rate: 0.5 mL/min; injection volume: 20 μ L; detector UV; column temperature: 23 °C. The fractions were concentrated under vacuum used a Rotavapor RE (Büchi, Germany) rotatory evaporation system.

Structural examination

The isolated iridoids were identified on the basis of their physical and spectroscopic properties. The basic information concerning the structure of compounds was provided by their NMR spectra.

Identification of isolated components

Melting points were measured with a melting point apparatus MP70 (Merck, Germany).

The UV spectra were recorded in MeOH and H_2O with Shimadzu UV 2101 PC spectrophotometer (Shimadzu Corporation, Japan).

¹H, ¹³C and 2D (COSY, NOESY, HMBC and HMQC) NMR spectra were recorded in MeOH-*d*, H_2O -*d* and DMSO-*d* sample tubes at room temperature, with a Bruker Avance DRX 400 spectrometer (Bruker, Germany), at 400 MHz (¹H) and 100 MHz (¹3C).

RESULTS AND DISCUSSION

Aerial parts of both *Stachys* species (*S. byzantina* and *S. germanica*) contained iridoids. Comparing the main iridoid component in the samples obtained from methanolic extract of drugs, harpagide was found in both *Stachys* samples. In addition to the iridoids in *S. byzantina*, ajugoside, aucubin and harpagide were identified by TLC (see Fig. 1), while those later two compounds were isolated and determined by RP-HPLC and NMR method aucubin and harpagide (see Tables 1 and 2). Harpagide and harpagoside (see Fig. 1) were detected in *S. germanica*. We could develop a method which can be used for the identification and detection of the iridoids of *Stachys* species.

In 1945, the Swedish botanist Erdtman subdivided this taxonomic family into two major subfamilies: the Lamioideae and the Nepetoideae. The Lamioideae subfamily





aucubin





harpagide

harpagoside

Figure 1. Isolated compounds.

ajugoside

Table 1. Physical and UV spectroscopic data on iridoids from S. byzantina and S. germanica.

Iridoids	M. P. [°C]	λ _{max} [nm]	
Ajugoside	amorph. powder	206	
Aucubin	179 – 183	210	
Harpagide	amorph. powder	210	
Harpagoside	amorph. powder	216	

M. P., melting point.

is characterized by tricolpate and binucleate pollen, albuminous seeds, spatulate embryos, the presence of iridoid glycosides, lower content of essential oils and rosmarinic acid but higher content of phenylpropanoid glycosides, whereas the Nepetoideae have hexacolpate, trinucleate pollen, exalbuminous seeds, investing embryos, the presence of volatile terpenoids, mainly monoterpenes and high content of essential oil and rosmarinic acid. Both subfamilies contain caffeic acid and its derivatives (Erdtman, 1945; Cantino & Sanders, 1992).

The genus Stachys belongs to the subfamily Lamioideae. Iridoids are a class of secondary metabolites found in this genus. The first investigation of the iridoid content of in three species dates back to the beginning of the 1970s, when Adema detected iridoid glycoside in S. palustris and when Ukrainian researchers determined harpagide and 8-O-acetylharpagide in 17 Stachys species (Adema, 1968; Zinchenko, 1972). The main iridoid components in the Stachys species studied by Gritsenko et al. in 1977 were harpagide and 8-O-acetylharpagide. The presence of aucubin was also detected in some Stachys species (Gritsenko et al., 1977). Ajugol, ajugoside, harpagide and 8-O-acetylharpagide were detected in S. atherocalyx, S. inflate and S. iberica (Komissarenko et al., 1976, 1979). In 1980, the research team started an examination concerning 20 different Stachys species, which supplemented the previous results: beside harpagide and acetylharpagide as the main components, reptoside and diacetyl-reptoside were also found (Pakaln

et al., 1980). In 1984, Lenherrr et al. performed the RP-HPLC analysis of 10 species belonging to the S. recta group, and melittoside, harpagide, acetylharpagide, ajugoside and ajugol were identified (Lenherrr, 1984). The data relating to the iridoids isolated until 1980 are summarized by El-Naggar & Beal (1980). El-Naggar's summary was followed by the work by Boros & Stermitz, which contains the summary of iridoids isolated between 1980 and 1990 (Boros & Stermitz, 1990, 1992). Russian researchers continued to investigate the chemical components of the Stachys species growing in Russia (Isamukhamedova & Pulakova, 1992; Kartev et al., 1994). Japanese researchers also conducted research into the iridoids Stachys species (Mivase et al., 1990). Monomelittoside, melittoside, 8-O-acetylharpagide, harpagide, ajugol, catalpol, 7-O-acetyl-8-epi-loganic acid, aucubin and 5-allosyloxyaucubin were isolated by research made by Montenegrian, Greek, Hungarian and Italian scientists (Háznagy-Radnai et al., 2005, 2006, 2007; Munoz & Pena 2001; Kostos et al., 2001; Meremeti et al., 2004; Serrilli et al., 2005).

The isolated iridoid components of *Stachys* species found in Hungary are included in Table 3. Háznagy-Radnai et al., 2006, 2007 two iridoids, as harpagide and 8-O-acetylharpagide isolated in *S. byzantina and S. germanica*. Ajugoside and aucubin in both species right now.

CONCLUSIONS

The genus *Stachys* L. is one of the largest genera of the family Lamiaceae and subfamily Lamioideae containing iridoids. Iridoids (aucubin, harpagide, ajugoside and harpagoside) were isolated and identified by combination of different chromatographic methods (NP-TLC, CPC and RP-HPLC) from *S. byzantina* and *S. germanica*. The structures were established by one- and two-dimensional NMR and mass spectrometry. *Stachys* species may also be used as a potential source of iridoids.

Aucubin (methanol):							
C/H	DEPT	δ _c	δ _н	J(Hz)	HMBC(C→H)		
1	СН	96.1	4.94 d	(7.1)	H-1′, H-3′, H-9		
3	СН	140.1	6.3 dd	(6.3, 1.8)	H-1, H-4		
4	СН	104.1	5.08 dd	(6.3, 4.0)	H-3, H-5		
5	СН	44.8	2.65 m		H-3, H-4, H-7, H-9		
6	СН	81.3	4.43 m		H-4, H-5, H-7, H-9		
7	СН	128.9	5.76 s		H-9, H-10		
8	С	81.2			H-7, H-9		
9	СН	46.5	2.89 t	(7.3)	H-1, H-7		
10	CH,	60.0	4.16 d	(15.4)	H-7		
			4.34 d	(15.4)			
1′	СН	98.5	4.67 d	(7.8)	H-1, H-2'		
2′	СН	73.5	3.22*		H-1′		
3′	СН	76.6	3.37*		H-1', H-2', H-4'		
4′	СН	70.2	3.28*		H-3′, H-5′, H-6′		
5′	СН	76.9	3.26*		H-1′, H-4′, H-6′		
6′	CH ₂	61.2	3.64 dd	(12.2, 5.2)	H-5′		
			3.85 d	(12.2)			

Table 2.¹H and ¹³C NMR spectral data for isolated iridoids.

Harpagide (methanol): C/H DEPT δ $\boldsymbol{\delta}_{_{\!H}}$ J(Hz) HMBC(C→H) 5.74 s 92.0 H-1′, H-3, H-9 1 CH 3 CH 141.3 6.31 d (6.5) H-1, H-4 (6.5, 4 CH 107.2 4.95 dd H-3, H-6, H-9 1.5) H-1, H-3, H-7, 5 С 70.4 H-9 77.0 3.70* 6 CH H-4, H-7, H-9 (13.8, 7 CH, 45.8 1.80 dd H-10 3.8) (13.8, 1.91 dd 4.8) 8 С 81.2 H-7, H-9 9 CH 58.5 2.55 s H-4, H-7, H-10 10 CH, 23.6 1.25 s H-7, H-9 1′ CH 98.1 4.58 d (8.0) H-1, H-2' (9.1, 2′ 3.21 dd H-1' CH 73.1 8.0) 3′ 76.4 3.38* CH H-1', H-2' 4′ CH 70.4 3.29* H-3' 5′ CH 77.0 3.30* H-4', H-6'

(11.8,

5.5)

(11.8)

H-5'

Table 3. The isolated iridoid components of Stachys species.

Species	Iridoids
S. alpina	harpagide, 8-O-acetylharpagide (Háznagy- Radnai, 2006, 2007)
S. annua	melittoside (Lenherr, 1984)
S. byzantina	harpagide, 8-O-acetylharpagide (Háznagy- Radnai, 2006, 2007)
S. germanica	harpagide, 8-O-acetylharpagide (Háznagy- Radnai, 2006, 2007)
S. grandiflora	harpagide, 8- <i>O</i> -acetylharpagide, melittoside (Háznagy-Radnai, 2006, 2007)
S. macrantha	harpagide, 8-O-acetylharpagide, ajugol, ajugoside, reptoside, allobetonicosid, macrathoside (Calis, 1991; Háznagy- Radnai, 2006, 2007)
S. officinalis	harpagide, 8-O-acetylharpagide, ajugol, ajugoside, reptoside, allobetonicosid, 6-O-acetylmioporoside (Kobzar, 1986; Derkach, 1987; Jeker, 1989; Háznagy- Radnai, 2006, 2007)
S. palustris	harpagide, 8-O-acetylharpagide, aucubin (Adema, 1968; Háznagy-Radnai, 2006, 2007)
S. recta	harpagide, 8- <i>O</i> -acetylharpagide, aucubin, ajugol, ajugoside, melittoside (Lenherr, 1984; Háznagy-Radnai, 2006, 2007)
S. sylvatica	harpagide, 8-O-acetylharpagide (Kukic, 2006; Háznagy-Radnai, 2006, 2007)

ACKNOWLEDGEMENTS

This work was supported by the Grant Agency of Ministry of Education, Science, Research and Sport of the Slovak (grants no. VEGA 2/0115/19 and VEGA 1/0359/18) and by the Slovak Research and Development Agency under the contract no. NKFI K 132044.

On the occasion of the 100th birth anniversary of our late teachers, nestors of Slovak Pharmacognosy, Prof. Dr. Ing. Jozef Tomko, DrSc. and Assoc.-Prof. Dr. PhMr. Jaroslav Kresánek, CSc.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

6′

CH,

61.4

3.66 dd

3.90 d

References

- Tomou EM, Barda Ch, Skaltsa HG. Stachys: a review of traditional uses, phytochemistry and bioactivity. Medicines. 2020;7(63):1-74.
- [2] Tutin TG, Heywood VH, Burges NA et al. Flora Europaea, Volume 3. Cambridge: University Press; 1972.
- [3] Skaltsa HD, Lazari DM, Chinou IB et al. Composition and antibacterial activity of the essential oils of *Stachys candida* and *S. chrysantha* from southern Greece. Planta Med. 1999;65:255-256.
- [4] Skaltsa HD, Mavrmmati A, Constantinidis T. A chemotaxonomic investigation of volatile constituents in *Stachys* subsect. *Swainsonianeae* (Labiatae). Phytochemistry. 2001;572:235-244.
- [5] El-Naggar LJ, Beal JL. Iridoids. A review. J Nat Prod. 1980;43:649-707.
- [6] Kobzar AY. Phytochemical study of *Betonica officinalis*. I. Isolation of biologically active substances from the aerial parts of the plant. Khim Prir Soed. 1986;2:239.
- [7] Derkach Al, Komissarenko NF; Pakalns D et al. Iridoids of some Stachys L. species. Rastit Resur. 1987;23:92-95.
- [8] Jeker M, Sticher O, Calis I et al. Allobetonicoside and 6-O-acetylmioporoside from *Betonica officinalis* L. Helv Chim Acta. 1989;72:1787-1791.
- [9] Calis I, Basaran AA, Saracoglu I, et al. Iridoid and phenylpropanoid glycosides from *Stachys macrantha*. Phytochemistry. 1992;3:167-169.
- [10] Boros CA, Stermitz FR. Iridoids. An Updated Review I. J Nat Prod. 1990;53:1055-1147.
- [11] Boros CA, Stermitz FR. Iridoids. An updated review. II. J Nat Prod. 1991;54:1172-1246.
- [12] Isamukhamedova MP, Pulatova TP. Iridoids of *Stachys betonicae* flora. Khim Prir Soed. 1992;5:586-587.
- [13] Kartev VG, Stepanichenko NN, Auelbekov SA. Chemical composition and pharmacological properties of plants of the genus *Stachys*. Khim Prir Soed. 1994;6:699-709.
- [14] Miyase T, Ueno A, Kitani T et al. Studies on *Stachys sieboldii* Miq.
 I. Isolation and structures of new glycosides. Yakugaku Zasshi. 1990;110:652-657.
- [15] Munoz O, Pena RC. Iridoids from Stachys grandidentata (Labiatae). J Biosciences. 2001;56:902-903.
- [16] Erdtman G. Pollen morphology and plant taxonomy, 4. Labiatae. Verbanaceae and Aviceniaceae, Svensk Bot Tidskr. 1945;39:279-285.
- [17] Cantino PD, Sanders RW. Subfamilial classification of Labiatae. Syst Bot. 1986;11:163-185.
- [18] Adema F. Iridoid glucosides of species of *Lamium* and some related genera. Acta Bot Neerl. 1968;17:423-430.
- [19] Zinchenko TV. *Stachys* and *Betonica* iridoids. Farm Zh (Kiev). 1972;27:86-87.
- [20] Gritsenko EN, Kostyuchenko OI, Fefer IM et al. Iridoids of some genera of the Labiatae family. Mater S'ezda Farm B SSR. 1977;3 164-166.
- [21] Komissarenko NF, Derkach AI, Sheremet IP et al. Harpagide and harpagide acetat of some species of the family Labiatae. Khim Prir Soed. 1976;1:109-110.

- [22] Komissarenko NF, Derkach AI, Sheremet IP et al. iridoids of Stachys inflata and Stachys iberica. Khim Prir Soed. 1979;1:99-100.
- [23] Pakaln DA, Komissarenko NF, Sheremet IP et al. Preliminary chemotaxonomic evalution of Caucasian species of the genus *Stachys*. Flory Ispol'z Ikh Nar Khoz. 1980;82-85.
- [24] Lenherr A., Meier B, Sticher O. Modern HPLC as a tool for chemotaxonomical investigations: iridoid glucosides and acetylated flavonoids in the group of *Stachys recta*. Planta Med. 1984;50:403-409.
- [25] Háznagy-Radnai E, Léber P, Tóth E et al. Iridoids of *Stachys* species growing in Hungary. JPC. 2005;18:314-318.
- [26] Kostos M, Aligiannis N, Mitaku S et al. Chemistry of plants from Crete: stachyspinoside, a new flavonoid glycoside and iridoids from *Stachys spinosa*. Nat Prod Lett. 2001;15:377-388.
- [27] Meremeti A, Karioti A, Skalska H, et al. Secondary metabolites from *Stachys ionica*. Biochem Syst Ecol. 2004;32:139-151.
- [28] Serrilli AM, Ramunno A, Piccioni F et al. Flavonoids and iridoids from *Stachys corsica*. Nat Prod Res. 2005;19:561-565.
- [29] Háznagy-Radnai E, Czigle Sz, Janicsák G et al. Iridoids of *Stachys* species growing in Hungary. JPC. 2006;19:187-190.
- [30] Háznagy-Radnai E. Examination of the volatile and non-volatile components of Hungarian *Stachys* species [Annals 146 of Albert Szent-Györgyi Medical & Pharmaceutical Center – dissertation]. Szeged: JATE Press; 2007.
- [31] Kukic J, Petrovic S, Pavlovic et al. Composition of essential oil of Stachys alpina L. ssp. dinarica Murb. Flavour Frag J. 2006;21:539-542.

EUROPEAN PHARMACEUTICAL JOURNAL



Rapid and simple CZE-UV method for quality control of B1 and B6 vitamins in drugs and dietary supplements

Special Issue Article

Matuskova M.¹, Cizmarova I.¹, Chalova P.^{1,2}, Mikus P.^{1,3}, Piestansky J.^{1,3}

¹Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, SK-832 32 Bratislava, Slovak Republic ²Biomedical Research Center of the Slovak Academy of Sciences, Institute of Virology, Dubravska cesta 9, SK-845 05 Bratislava, Slovak Republic ³Toxicologic and Antidoping Center, Faculty of Pharmacy, Comenius University in Bratislava, Slovak Republic SK-832 32 Bratislava, Slovak Republic

Received 15 June, 2021, accepted 17 June, 2021

Abstract The application of hydrodynamically closed capillary zone electrophoresis combined with convenient ultraviolet (UV) detection allows fast, simple, environmentally friendly and cost-effective analysis of ions or ionisable molecules. This technique has been used to determine two selected B vitamins (thiamine, pyridoxine) in various drug formulations. The developed method was characterised by excellent validation parameters, such as linearity, precision, accuracy, limit of detection and limit of quantification. The total time of analysis was lower than 13.5 min. The results indicate that the method is suitable for implementation in routine quality control of selected B vitamins in pharmaceutical and food samples.

Keywords capillary zone electrophoresis - hydrodynamically closed system - ultraviolet detection - thiamine - pyridoxine - quality control

INTRODUCTION

Quality, safety and efficacy are the main drug attributes. The therapeutic effect depends on the exact amount of an active substance present in the medicine. Doses higher than therapeutic ones are often responsible for adverse and toxic effects. On the other hand, the use of lower doses cannot achieve the demanded benefit to human health. It is known that the active substances undergo decomposition processes due to the environmental effects. The quantity of the original drug can be reduced and the related degradation products can form. Typically, they have a negative impact on the drug quality and could represent a potential health risk. Therefore, measurement of the active substance in medicine is necessary to ensure its high quality.

Thiamine (THI) and pyridoxine (PYR) belong to a wide group of B vitamins. As active substances in drugs, they are indicated in nervous system diseases – for example, polyneuropathy, neuritis, herpes zoster, myalgia and states with B_1 and B_6 deficiency (Calderón-Ospina & Nava-Mesa, 2020). They are also offered as dietary supplements in order to provide them

in sufficient amounts. THI and PYR can be administered in various dosage forms – injections, tablets, film-coated tablets, capsules or capsules with modified release.

Electrophoretic separation methods, especially capillary zone electrophoresis (CZE), seem to be useful in the analysis of active substances. CZE is simple to use, economical and ecological (consumption of low amount of sample and organic solvents) and is characterised by a high separation efficiency (Řemínek & Foret, 2021). These facts make it suitable for routine use in pharmaceutical analysis, which is demonstrated in some papers published by our laboratory group dealing with the analysis of antigripal drugs (Maráková et al., 2013), inflammatory bowel disease drugs (Maráková et al., 2017), vitamins (Maráková et al., 2014) or drugs used to treat tobacco use disorder (Piešťanský et al., 2013).

We have recently proposed a CZE method in a hydrodynamically closed separation system to determine THI and PYR in commercial beverages and food supplements (Matušková et al., 2020). Here, we used this method (with

^{*} E-mail: piestansky@fpharm.uniba.sk

³ Open Access. © 2021 European Pharmaceutical Journal, published by Sciendo. COBYNC-NOT This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

some minor modifications) to analyse THI and PYR content in various dosage forms and dietary supplements (Fig. 1a–c).

MATERIALS AND METHODS

Thiamine hydrochloride, pyridoxine hydrochloride and chemicals used for electrolyte system solution preparation (y-aminobutyric acid [GABA], acetic acid [HAc], methylhydroxyethylcellulose [m-HEC]) were obtained from Sigma-Aldrich (Steinheim, Germany) and Serva (Heidelberg, Germany). Deionised water (18.2 M Ω cm) was used for the preparation of all solutions. The experiments were performed on EA 102 apparatus (Villa Labeco, Spisska Nova Ves, Slovakia) in a CZE single-column arrangement. A separation column was provided with a 300-µm internal diameter (i.d.) polytetrafluorethylene (PTFE) capillary tube of total length 90 mm and a contactless conductivity detector. The background electrolyte (BGE) was composed of 25 mM GABA + 50 mM HAc + 0.5% m-HEC (pH = 3.7). The samples were injected by a 200-nL internal sample loop of the injection valve of the analyser. All experiments were performed in a constant current mode. The driving current was 50 µA. An ultraviolet (UV) spectrophotometric absorbance detector (Knauer, Berlin, Germany) was connected to an on-column photometric detection cell via optical fibres. The detector was set at 260 nm.

Preparation of the sample for analysis depended on the pharmaceutical formulation. Here, three types of formulations were analysed - injections (Milgamma NA inject; Wörwag Pharma, Böblingen, Germany), film-coated tablets (B-komplex Sanofi; Zentiva, Prague, Czech Republic) and capsules (Diclovit, G.L. Pharma, Lannach, Austria). Preparation of injections was accompanied only by simple dilution with demineralised water at an appropriate concentration level. Pharmaceuticals formulated as film-coated tablets and capsules were crushed into a fine powder. An amount of the powder equivalent to the weight of one tablet (or capsule) was transferred to a 100mL volumetric flask using demineralised water. The solution was sonicated for 30 min, filtrated using Whatman filter paper No.1 and diluted (if needed) with demineralised water. These solutions were then directly analysed using CZE as described above.

RESULTS AND DISCUSSION

At first, it was necessary to prove the proposed method for the demanded purpose. Therefore, we validated the modified CZE-UV method according to the ICH Q2(R1) guideline (ICH Harmonised Tripartite Guideline, 2005) recommendations. All resulting statistical data and performance parameters of the CZE-UV method are summarised in Table 1.

The method provided favourable parameters such as separation efficiency (N) and sample loadability, which resulted in sub- μ g/mL limit of detection (LOD) and limit of quantification (LOQ) values. An illustrative electropherogram

Table 1. Performance parameters of the CZE-UV method.

	Thiamine	Pyridoxine
t _m (min)	7.01	11.02
RSD _{tm} (%), n = 6	0.28	0.76
RSD _{area} (%), n = 6	2.28	8.60
a (mAU)	134.76	-39.09
RSD _a (%), n = 6	2.27	1.33
b (mAU/μg mL)	94.77	36.22
RSD _b (%), n = 6	0.49	0.29
r ²	0.9996	0.9990
Linear range (µg/mL)	0.5–100	1–100
LOD (µg/mL)	0.08	0.15
LOQ (µg/mL)	0.25	0.50
N	7900	6400
R	8.	81

LOD and LOQ were calculated as the signal (S) to noise (N) ratios to be $3 \times S/N$ and $10 \times S/N$, respectively. Separation efficiency (N) was calculated according to the equation $N = 5.545^*(t_m/w_{1/2})^2$, where t_m is the migration time and $w_{1/2}$ is the full width at half maximum of the peak. The calibration curve is expressed by the equation y = b.x + a. RSD t_m and RSD are were calculated from the samples at LOQ concentration level. Resolution (R) was calculated according to the equation $R = 1.18^*(t_2 - t_1)/(w_{1/2} TH) + w_{1/2} PYR)$, where t_2 is the migration time of PYR, t_1 is the migration time of THI, $w_{1/2} TH$ is the full width at half maximum of the PYR peak.

obtained from the analysis of THI and PYR standards at 0.25 µg/mL concentration level (LOQ of THI and concentration close to LOD of PYR) is presented in Fig. 1d. The enhanced sample loadability resulted from the use of wide-bore (300 µm i.d.) separation capillary tubes, which are typical for a hydrodynamically closed separation system. In comparison to our previous work (Matušková et al., 2020), the use of shorter separation column resulted in faster analysis of THI and PYR. Excellent linearity of the calibration lines (concentration range 0.5-100 µg/mL) is indicated by the coefficient of determination (r²) values. Acceptable repeatability was confirmed by the values of relative standard deviations (RSD) of migration time (RSD_{tm}), peak area (RSD_{area}), intercept a(RSD_) and slope b (RSD_) of the calibration lines. Critical factor of the validation procedure was the recovery parameter. The recovery experiment was performed by spiking the tested pharmaceutical dosage forms with THI and PYR standards at three concentration levels. Representative records, shown in Fig. 1e, illustrate the sample profile characteristics for THI and PYR in the original and spiked (at three concentration levels -5, 10 and 25 µg/mL) commercial drug Diclovit.

Recovery values, calculated for the THI and PYR detection response in the standard (water) and tested drug matrices (injection solution, film-coated tablets, capsules; see Fig.



Figure 1. Analysis of THI and PYR in various pharmaceutical dosage forms – a) injection solutions Milgamma NA, b) film-coated tablets B-komplex Sanofi and c) capsules Diclovit. d) Illustrative electropherogram of THI and PYR at the concentration level 0.25 μ g/mL. e) Illustrative electropherogram obtained from the CZE-UV analysis of non-spiked and spiked drug Diclovit. The spiked concentrations of THI and PYR were 5, 10 and 25 μ g/mL. The injected volume was 200 nL.

1a–c), were in the range 95%–115% for THI and 90%–107% for PYR. This indicated acceptable effect of the matrix on the analyte signal and acceptable accuracy of the method.

After the successful validation procedure, the proved CZE-UV method was applied to determine the content of THI and PYR in real pharmaceutical samples. The obtained results are summarised in Table 2. The measured data were in good agreement with the declared content. Only in case of film-coated tablets (B-komplex Sanofi), the determined content of THI was slightly higher than 15% in comparison to the declared one. This variation might be caused due to changes during the storage and manufacture. However, B-komplex Sanofi is classified as a dietary supplement. For such preparation, there is no strict adherence to the active compound content.

In conclusion, the present work illustrates the potential of simple CZE-UV method performed in hydrodynamically closed separation system for the quality control of THI and PYR present in pharmaceutical samples. The advantages of such an analytical system were demonstrated by the excellent performance parameters of the CZE-UV method and its successful application in the drug and dietary supplements' quality control area. This method is suitable for the automation

Table 2. THI and PYR concentrations in three pharmaceutical samples determined by the CZE-UV method.

		Parameters			
Preparation		Found ± SD (µg/mL)	RSD (%), n=3	Declared (µg/mL)	
Milgamma	THI	53.15 ± 0.26	0.49	50	
NĂ (inj)	PYR	23.01 ± 0.23	0.98	25	
Diclovit (cps)	THI	50.81 ± 1.27	2.50	50	
	PYR	43.18 ± 1.07	2.48	50	
B-komplex Sanofi (tbl flm)	THI	11.59 ± 0.18	1.56	10	
	PYR	5.52 ± 0.50	9.00	5	

and miniaturisation and it has promising potentialities to be used in the reference and routine pharmaceutical laboratories. Owing to being a rapid, cheap, available and reliable analysis, the presented CZE-UV approach represents a suitable alternative to the well-established analytical methods used in drug and food analysis. Rapid and simple CZE-UV method for quality control of B1 and B6 vitamins in drugs and dietary supplements

ACKNOWLEDGMENTS

This work was supported by the projects VEGA 1/0463/18, APVV-15-0585, KEGA 027UK-4/2020, FaF UK/2/2021, FaF UK/3/2021 and the grant of Comenius University UK/235/2021 and was carried out in the Toxicologic and Antidoping Center at the Faculty of Pharmacy Comenius University.

References

- Calderón-Ospina CA, Nava-Mesa MO. B vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin. CNS Neurosci Ther. 2020; 26: 5–13.
- [2] ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology. Step 4 Version. European Medicines Agency, November 2005 (http://www.ich.org/cache/ compo/276-254-1.html). Accessed June 9, 2021.
- [3] Maráková K, Piešťanský J, Havránek E, Mikuš P, Simultaneous analysis of vitamins B in pharmaceuticals and dietary supplements by capillary electrophoresis hyphenated with triple quadrupole mass spectrometry. Pharmazie. 2014; 69: 663–668.
- [4] Maráková K, Piešťanský J, Mikuš P. Determination of drugs for Crohn's disease treatment in pharmaceuticals by capillary electrophoresis hyphenated with tandem mass spectrometry. Chromatographia. 2017; 80: 537–546.

CONFLICT OF INTEREST STATEMENT

The authors do not have any conflict of interest concerning the present work.

- [5] Maráková K, Piešťanský J, Veizerová L, Galba J, Dokupilová S, Havránek E, Mikuš P. Multidrug analysis of pharmaceutical and urine matrices by on-line coupled capillary electrophoresis and triple quadrupole mass spectrometry. J Sep Sci. 2013; 36: 1806– 1816.
- [6] Matušková M, Čižmárová I, Mikuš P, Piešťanský J. Stanovenie tiamínu a pyridoxínu vo výživových doplnkoch a nápojoch jednoduchou metódou kapilárnej zónovej elektroforézy v spojení s UV detekciou. Čes. Slov. Farm. 2020; 69: 237–243.
- [7] Piešťanský J, Maráková K, Veizerová L, Galba J, Mikuš P. Stanovenie vareniklínu v lieku Champix[®] dvojdimenzionálnou kapilárnou elektroforézou v spojení s UV detekciou. Čes. Slov. Farm. 2013; 62: 270–275.
- [8] Řemínek R, Foret F, Capillary electrophoretic methods for quality control analyses of pharmaceuticals: A review. Electrophoresis. 2021; 42: 19–37.



EUROPEAN PHARMACEUTICAL JOURNAL



Drug Technology in Hunting Practice

Original Paper

Laca Megyesi S.^{1^I}, Königová A.¹, Molnár L.², Várady M.¹, Fedorová M.³, Eftimová J.⁴

¹Institute of Parasitology, Slovak Academy of Sciences, Hlinkova 3, 04001 Košice, Slovakia ²Clinic for Birds and Exotic Animals, University of Veterinary Medicine and Pharmacy, Košice, Slovakia ³Department of Pharmacy and Social Pharmacy ⁴Department of Pharmaceutical Technology, Pharmacognosy and Botany

Received 15 June, 2021, accepted 17 June, 2021

Abstract Antiparasitic therapy in living ratites is based on the right dose and efficacy is only when the drug is pharmaceutically stable and safe. Ivermectin is considered to be the most widely used drug in the treatment of parasitosis in ruminants worlwide. For these reasons, in our study, we focused on the pharmaceutical investigation of ivermectin by SEM analysis of its powder particle shape and size, flow properties of solids (angle of repose, compressibility index, Hausner ratio) and zeta potential.

Keywords wild ruminants - Galmectin premix - ivermectin - flow properties

INTRODUCTION

Frequent occurrence of wild and domestic ruminants together on common pastures raises the question about the role of wild species in the transmission of gastrointestinal (GI) nematodes between small ruminants. The similar feeding habits of wild and domestic ruminants may represent a high potential risk for the transmission of GI nematodes from wild to domestic sheep and goats. Hunters are required to estimate the total number of animals and their total weights in hunting districts. The distribution of drugs in the feed may thus be easily inconsistent, so the drugs may be underdosed. Underdosing is one of the most common managerial flaws contributing to the development of anthelmintic resistance (AR) (Torres-Acosta and Hoste, 2008). Ivermectin (IVM) is one of the best known and most widely used antiparasitic drugs in human and veterinary medicine. IVM is a semi-synthetic product obtained from avermectin, naturally synthesised by the microorganism Streptomyces avermitilis. It consists of a mixture of two homologues, dihydroavermectin $B_{1,2}$ ($H_2B_{1,2}$) and dihydroavermectin B_{1b} (H_2B_{1b}) (Cerkvenik et al., 2001). The aim of our study was to analyse two samples of Galmectin premix stored at different temperatures and humidity for 1 month using scanning electron microscope (SEM) analyses and flow properties, in order to determine the effect of the external environment on the structure of the premix.

MATERIALS AND METHODS

Chemicals: IVM in Galmectin 0.150 mg/g premix (PHARMAGAL Ltd., Nitra, Slovakia)

Data treatment

Sample No. 1 was stored at 20 °C, 58% humidity in a glass vessel and sample No. 2 was stored at 4.2 °C, 75% humidity in a glass vessel. Samples of the premix (Sample No. 1 and Sample No. 2) for SEM analysis (MIRA3, TESCAN) were observed in the dried state. We placed them on a base plate with a size of about 1 cm². According to Kostelanská recommendations (2017), the samples should be coated with a layer of metal with good thermal and electrical conductivity (gold, silver, platinum, carbon or an alloy of platinum and palladium) before observation. In this case, we used a layer of carbon (about 20 nm), which we applied using a sputtering device. The carbon layer provided the samples with a negative charge and a heat circuit in which most of the energy of the accelerated primary electrons was converted. The prepared premix samples were placed in a chamber placed in the lower part of the microscope tube. Samples of the premix were placed on a trigonometric table, near which detectors of individual signals (secondary and reflected electrons) were placed.

Compressibility index is a measure of strength and stability, and Hausner ratio is a measure of the interparticulate friction.

^{*} E-mail: stefania.megyesiova@uvlf.sk

³ Open Access. © 2021 European Pharmaceutical Journal, published by Sciendo. CC) BY-NC-ND This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Drug Technology in Hunting Practice

Flow character is rated based on compressibility index and Hausner ratio.

Compressibility index = $100(V_0 - V_f)/V_0$ Hausner ratio = V_0/V_f

where: $V_0 = original bulk volume of powder; V_f = final tapped volume of powder.$

Zeta potential measurement was performed using ZetaSizer ZS device, working on the principle of laser Doppler velocimetry (LDV) in combination with Dynamic Light Scattering (DLS). After switching on, the instrument was calibrated and heated to a measuring temperature of 25 °C. First, the sample was dispersed in 100 ml of distilled water. Then we transferred the solution to the measuring cuvette with a syringe. We used the configuration of the signal passed through the sample. The device automatically evaluated the standard deviation and displayed it together with the zeta potential value in the software program.

RESULTS AND DISCUSSION

SEM analysis of the particle shape of sample No. 1 stored at 20 °C, 58% humidity in a glass vessel revealed an angular particle shape at 500× magnification. Particles with a smooth surface and a regular shape had better flow properties than square-shaped particles that fit together. We confirmed this fact at a magnification of 3,000 times, where we found that the individual particles of the examined sample really fit into each other. At 8,000 and 20,000 times magnification, we confirmed the angular, irregular shape of the particles and also observed small particles on the surface of larger particles.

When comparing the SEM analysis of the particle shape of sample No. 1 and sample No. 2 at 500× magnification, it is clear that in the case of sample No. 2, the individual particles were compacted under the influence of moisture. At 500× magnification of sample No. 2, we could clearly see that the space between the particles had shrunk and they tended to clump together. At 3,000× magnification, we found a more rounded shape of the particles of sample No. 2.

The second part of the SEM analysis was the measurement of individual particles. We measured the particles at 1,500 and 4,000 fold magnification. In sample No. 1, we measured a total of 24 randomly selected particles. The average particle size was 12.24 μ m. On evaluating the SEM analysis of the particle size of sample No. 2 at 1,500 × magnification, we also observed isolated agglomerates of 42.16 and 39.30 μ m. As with sample No. 1, we selected 24 particles at 1,500 and 4,000 fold magnification. The average size of the individual particles was 12.65 μ m. According to our calculations, the compressibility index values ranged from 2.85% to 7.69%, which means that the nature of the flow of sample No. 1 was excellent. The Hausner ratio values ranged from 1.02 to 1.08, which again

confirms the result of the compressibility index calculation. This result shows that in the case of storage conditions (temperature 20 °C, humidity 58%), the flow properties of the premix do not deteriorate. The compressibility index values of sample No. 2 ranged from 2.98% to 5.00%, which resulted in an excellent flow pattern of the sample. The Hausner ratio values ranged from 1.03 to 1.05, which also indicates the excellent nature of the flow of the examined sample No. 2.

Angle of repose measurement results ° \pm SD of sample No. 1 and sample No. 2 were repeated three times for each sample. According to the generally accepted Carr scale, powder with a pour angle below 30° has good flowability, 30°–45° shows some cohesiveness, 45°–55° shows real cohesiveness and powder with a pour angle above 55° is characterised by very high cohesiveness and very limited flowability. It follows from the above that the samples examined by us had a pour angle in the range of 30°–45° and showed certain coherence.

The Zeta potential of both Galmectin 0.150 mg/g premix powder samples examined was measured using a ZetaSizer (Malvern, UK), which recorded the results, and these were subsequently processed into Zeta potential distribution and electrophoretic mobility distribution. When evaluating the results of the analysis, we assumed that if the Zeta potential was in the range of -30 to +30 mV, then the charge on the surface was too small to prevent contact and the particles tended to agglomerate. The measurement was performed in three cycles, each cycle containing 10 measurements for 10 seconds. The resulting Zeta potential measurement was created as the average of all measurements. The instrument recorded one peak in both cases. Zeta potential of sample No. 1 was -18.7 ± 6.27 mV, so it tended to clump. Zeta potential of sample No. 2 had a value of -17.2 ± 9.22 mV, which showed that similar to sample No. 1, sample No. 2 also tended to clump. Differences in the measured values of Zeta potential of sample No. 1 and sample No. 2 were insignificant, indicating that the effect of external conditions did not affect the stability of the samples.

. The effect of moisture on the powder shape was determined from the SEM analysis. The sample which was exposed to moisture showed a more rounded shape and also the formation of agglomerates. Based on the obtained results of the pharmaceutical analysis, we propose that in hunting practice, premixes have to be stored in well-sealed bags that protect against the effects of moisture.

ACKNOWLEDGEMENT

This study was supported by funds from the Scientific Grant Agency VEGA 2/0099/19.

CONFLICT OF INTEREST STATEMENT

The authors declare that they have no conflicts of interest.

Megyesi Š. et al.

References

- Cerkvenik V, Doganoc DZ, Skubic V, Beek WMJ, Keukens HJ. Thermal and long-term freezing stability of ivermectin residues in sheep milk. Eur Food Res Technol. 2001;213:72–6.
- [2] Kostelanská K, Gajdziok, J. Elektrónová mikroskopie pro předmět Instrumentální analytické metody ve farmaceutické technologii.
 Brno: 2017.
- [3] Torres-Acosta JFJ, Hoste H. Alternative or improved methods to limit gastro-intestinal parasitism in grazing sheep and goats.
 Small Rum Res. 2008; 77:159–173.



EUROPEAN PHARMACEUTICAL JOURNAL



Phospholipid bilayers in model membranes and drug delivery systems: from physics to pharmacy

Special Issue Article

Uhríková D.⊠

Department of Physical Chemistry of Drugs, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, 832 32 Bratislava, Slovakia

Received 16 June, 2021, accepted 17 June, 2021

Abstract Lipids spontaneously aggregate in an aqueous environment forming supramolecular structures of various architectures known as liquid crystalline mesophases. Their thermodynamic properties determined by dual polar/apolar nature coupled with the possibility to modulate the structural parameters, phase geometry and stability are challenging for applications in drug delivery systems. We review a few examples of functionality of lipid bilayers.

Keywords lipid bilayer – non-lamellar phases – antimicrobial peptides – lipoplexes – pulmonary surfactant

Amphiphilic molecules of lipids self-assemble in water to minimise the exposure of their hydrophobic moieties to water. It was found that both the energetics at the lipid-water interface and the lipid molecular shape play a very important role in the aggregation and formation of resultant structures. While the hydrophobic interaction has a tendency to decrease the total surface area, repulsive interactions tend to increase the surface area. These opposing forces give rise to an optimal equilibrium area per lipid molecule. Packing restrictions determine the curvature of lipid monolayer and can also give rise to an optimum aggregate size (Israelachvili et al., 1976). Thus, the hydrophobic effect and structural diversity of lipidic molecules are responsible for the formation of a high variety of their supra-molecular assemblies. Fig. 1 illustrates a few structures of the lyotropic liquid crystalline mesophases formed by lipids: (A) one-dimensional lamellar phase known as multilamellar liposomes (onion-like structure) in excess of water; (B) two-dimensional columnar hexagonal phase and (C) three-dimensional cubic phases of symmetries characterised by space groups. Multilamellar and particularly unilamellar liposomes formed by single lipid bilayer frequently serve as a model system of lipid bilayer of biological membrane. Lipidic mesophases attract attention due to their capability to accommodate a drug into both the water phase and the hydrophobic matrix. Since 1975, when the first demonstration of the improved *in vivo* activity of liposome-entrapped anticancer drug in animal models proved successful treatment of mice bearing leukaemia (Kobayashi et al., 1975), a wide variety of lipidic drug delivery systems have been employed. Here, we review a few examples of functionality of lipid bilayers.

LIPID BILAYERS AS A MODEL OF BIOLOGICAL MEMBRANE

Antimicrobial peptides (AMPs) emerged as an interesting alternative to antibiotics that fight against infectious diseases. AMPs are considered membrane-active agents leading to cell death by acting on the phospholipid membrane. All proposed bactericidal mechanisms have the same main initialisation adsorption of AMPs onto the membrane due to electrostatic interactions between the cationic peptides and the accessible anionic groups of hydrophilic phospholipid headgroups at the membrane surface. Thereafter, accumulation and positional change eventually lead to the formation of pores, membrane permeabilisation or its micellisation (Teixeira et al., 2012). The interaction must be selective regarding the distinction between mammalian cells and pathogen cells (bacteria, fungi, protozoa). Thus, knowledge of the details of AMPs interaction with lipid bilayers of composition mimicking the pathogen membrane is of great importance to evaluate their antimicrobial activity. Small-angle X-ray and neutron scattering (SAXS and SANS, respectively) studies can

^{*} E-mail: uhrikova@fpharm.uniba.sk

³ Open Access. © 2021 European Pharmaceutical Journal, published by Sciendo. COBY-NC-ND This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Phospholipid bilayers in model membranes and drug delivery systems: from physics to pharmacy



Figure 1. Lyotropic liquid crystalline mesophases: (A) multilamellar vesicles; (B) inverted hexagonal phase; (C) cubic phase of Pn3m space group.



Figure 2. (A) SANS curves of POPE/POPG vesicles; (B) CAM– POPE/POPG at P:L = 1:10 mol/mol (POPE/POPG = 3:1 mol/mol). Full lines represent fitting curves.



Figure 3. Multilamellar CAM–POPE/POPG structure identified at liquid crystalline state of the lipids (36 °C). d – repeat distance.

give the necessary information on the AMPs' ability to affect the structure and integrity of the membrane.

We studied the interaction of cecropin A-melittin (CAM, nominal charge +6), a hybrid peptide composed of the cationic region of cecropin A and the hydrophobic and non-haemolytic region of melittin with a bacterial model lipid membrane composed of zwitterionic palmitoyl-oleoylglycerophosphoethanolamine (POPE) and negatively charged palmitoyl-oleoyl-phosphoglycerol (POPG). SANS and SAXS were used to unravel the mechanism of the peptide antimicrobial activity as described in Silva et al. (2018). Fig. 2A depicts the normalised SANS intensity as a function of the scattering vector q of POPE/POPG oligolamellar vesicles with the lipid bilayer thickness being d, ~ 39.4 Å. SANS data were analysed using SasView software. Fig. 2B shows the I(q) of CAM-POPE/POPG mixtures at P:L = 1:10 mol/mol and 36 °C. When the vesicle dispersion is mixed with the CAM peptide, a fine white precipitate spontaneously forms, suggesting massive aggregation and condensation of the lipid bilayers induced by the peptide. CAM interacts strongly with the negatively charged bilayer and induces extensive vesicle disruption, forming a condensed 'onion-like' multilamellar structure with repeat distance $d = 2\pi/q_o \sim 50.0$ Å as derived from the maximum of the observed peak and confirmed by SAXS (not shown). Fig. 3 shows a sketch of the proposed multilamellar structure of CAM-POPE/POPG mixture. We propose that this peptide exerts its antimicrobial action through extensive membrane disruption, leading to cell death.

In another study (Silva et al., 2013), the bilayer composed of dimyristoylphosphatidylcholine/dimyristoylphosphoglycerol (DMPC/DMPG = 3:1 mol/mol) mimicking the membrane of *Candida albicans* interacted with AMP of the lactoferrin family (LFchimera, nominal charge +12). Fig. 4 shows the SAXS pattern of two bicontinuous cubic phases detected due to disintegration of the membrane by pore-forming mechanism. These results illustrate variedness in the antimicrobial mechanism of AMPs acting on the lipid membrane.



Figure 4. SAXS pattern of a mixture of LFchimera and DMPC/DMPG at P:L = 1:21 mol/mol (t = 24 °C). Peaks of detected cubic phases Pn3m (black) and Im3m (blue) are assigned to spacing $\sqrt{(h^2 + k^2 + l^2)}$, where h, k and I are Miller indices. Models of cubic phases of Pn3m and Im3m space group.

LIPID BILAYERS IN DNA DELIVERY SYSTEM

Lipoplexes are formed due to the electrostatic interaction between positively charged liposomes and DNA polyanion. Positively charged complexes show enhanced interaction with the negatively charged cytoplasmic membrane and, therefore, higher cellular uptake via endocytosis. However, for successful DNA delivery, lipoplexes must escape from the endosome inside the cell and DNA must be released from the complex in cytoplasm. High positive surface charge density of the lipoplex is crucial for a successful endosomal fusion. On the other hand, it can be an obstacle for DNA release from the complex. A way to overcome this problem is to use pH-sensitive surfactants with pK_{1} between 4.5 and 8. Acidic pH inside of endosome secures lipoplexes' fusion with the endosomal membrane. In the cytoplasm, at neutral pH, the surfactants are uncharged and DNA can be easily released from the lipoplex via dissociation.

We prepared pH-sensitive liposomes composed of homologues of series of *N*,*N*-dimethyl-alkane-1-amine *N*-oxides (*Cn*NO, n = 8-18, where *n* is the number of carbon atoms in the alkyl substituent) (Devínsky et al., 1978) and neutral phospholipid dioleoylphosphatidylethanolamine (DOPE) at a molar ratio *Cn*NO/DOPE = 0.4 and tested them for *in vitro* transfection activity. Several techniques (SAXS, UV– VIS, zeta potential measurements, confocal microscopy) were applied to characterise the system in an effort to unravel the relationship between the transfection efficiency, structure and composition of the lipoplexes (for details, see Liskayová et al., 2019). Fig. 5 summarises the most important findings underlining the connection between structural changes (studied by SAXS) and transfection activity. In acidic conditions, DNA-C8NO/DOPE at C8NO/DOPE = 0.4 mol/mol forms a condensed inverted hexagonal phase (H_{μ}^{C}) . In this structure, the DNA strands are inserted in hexagonally arranged tubules created by the surfactant/lipid mixture (Fig. 1B). Note that the complexes prepared with C8NO keep their structure in neutral/alkaline solutions also. CnNOs with longer hydrophobic alkyl substituent, $n \ge 10$, induce structural changes. SAXS revealed the coexistence of two phases, condensed lamellar $L_a^{\ C}$ phase and $H_{\mu}^{\ C}$ in the complexes DNA–CnNO/DOPE, $n \ge 10$. Commensurate lattice parameters, the repeat distance d_{ic} of L_a^{C} phase and the lattice parameter of the H_{μ}^{C} phase $(d_{\mu} \approx a_{\mu})$ indicate an epitaxial relationship, we abbreviate the structure as $L_a^{C} \& H_{\mu}^{C}$. The connection through the common scattering plane facilitates the transition of the lipid between the two different structures. The structure changed in neutral/ slightly alkaline solutions. A lamellar phase (L_{a}) is a dominant structure in all studied mixtures. In addition, SAXS patterns of complexes DNA-CnNO/DOPE, n=16 and 18, indicate the presence of a bicontinuous Pn3m cubic phase. The lattice parameter a_o was found to be $a_o \sim 17-18$ nm for detected cubic phases. Bicontinuous cubic phases (Q_n) are formed by a pair of interpenetrating, but non-contacting aqueous channels separated by a single, continuous lipid bilayer. Even if the lattice parameter of *Pn3m* is rather big (17–18 nm), three-dimensional arrangement of lipid bilayer in the cubic network requires its high negative curvature that might bring difficulties to accommodate bulky DNA molecules. To summarise, the change of pH from acidic to neutral induces phase transition $L_{a}^{c} \& H_{\mu}^{c} \to Q_{\mu} + L_{a'}$ which allows DNA release from the lipoplexes.



Figure 5. SAXS patterns of DNA–CnNO/DOPE complexes (n = 8, 10, 16 and 18) prepared at CnNO/DOPE = 0.4 mol/mol in aqueous solutions at acidic and neutral/slightly alkaline conditions, respectively. Transfection efficiency of CnNO/DOPE (n = 8-18) complexes tested on U2OS cells.

Transfection efficiency for plasmid DNA (pDNA, EGFP-N1) was tested on human bone osteosarcoma epithelial cells (U2OS line) and evaluated after 24 and 48 hours by flow cytometry. Commercially available Lipofectamine 2000 (LF) was used as a control. Transfection efficiency follows a quasi-parabolic dependence on the length of CnNO alkyl substituent n, with the maximum found at n = 16. The complex of C16NO/ DOPE was found to be ~3 times more efficient than LF. Our findings support the hypothesis that the lipids of Q. phase favour membrane pore formation resulting from fusion of the lipoplex cubic structure with endosomal membrane. Pores, in turn, allow for cytoplasmic gene delivery. Due to pH sensitivity of our lipoplexes, we can hypothesise synergy of two processes enhancing transfection: a massive release of DNA during $L_a^{\ c} \& H_{\mu}^{\ c} \to Q_{\mu} + L_a$ phase transition and its easier internalisation in the cell supported by the propensity of Q_{μ} for pore formation.

LIPIDS AS A DRUG

Pulmonary surfactant (PS) is a surface active film lining the alveoli of the lung (Fig. 6A). Its principal function is to lower the surface tension at the air/liquid interface, facilitate the exchange of gasses and stabilise alveoli during breathing. PS is composed of ~90% lipids and 8%–10% of a few specific surfactant-associated proteins. Phospholipids predominate; saturated dipalmitoylphosphatidylcholine (DPPC) is the most abundant in PS of mammals, up to ~50% by mass. Unsaturated phosphatidylcholines (PC) create ~20% and a smaller fraction (~10%) of anionic species such as POPG.

A high content of DPPC plays a key function to reach the necessary, extremely low surface tension (<1 mN/m). Hydrophilic SP-A, SP-D and hydrophobic SP-B, SP-C are surfactant-associated specific proteins. SP-B is crucial for proper spreading of the lipid interfacial monolayer. The surface active function of PS is critically dependent on the existence of a multilayered film (~100 nm in thickness) at the air–water interface. An inactivation, deficiency or an absence of PS results in respiratory distress syndrome (RDS) that can be lethal for premature babies. RDS is therapeutically treated by application of PS preparations obtained from animals (exogenous natural), like porcine Curosurf[®] or bovine Survanta[®].

The exogenous natural PS contains at least 50 different phospholipids and a small fraction of hydrophobic proteins (\sim 1–2 wt%) (Calkovska et al., 2016). Morphologically, it is a mixture of various vesicles, from unilamellar through oligolamellar up to multilamellar.

We studied the effect of bacterial toxin, lipopolysaccharide (LPS), on the structure of clinically modified porcine pulmonary surfactant, mimicking pathological conditions. Consecutively, Polymyxin B (PxB), a cyclic amphiphatic antibiotic, was applied. Fig. 6B shows the SAXS patterns of modified porcine surfactant at 37 °C when the mixture is in liquid crystalline state (fluid phase). Two peaks (*L1* and *L2*) belong to a lamellar phase with repeat distance $d \sim 8.35$ nm. LPS affects the multilamellar packing of PS. Longer incubation (~2 hours) generates a large swelling up, which corresponds to a SAXS pattern of large unresolved peak of low intensity with a subtle shoulder at low $q \sim 0.5$ nm⁻¹. The pattern indicates



Figure 6. (A) Schematic representation of pulmonary surfactant; (B) SAXS pattern of modified porcine surfactant, surfactant incubated with 10% of LPS for 2 hours and surfactant/LPS 10% with addition of 2% of PxB (at 37 °C).

swelling of a lamellar phase up to periodicity ~12–13 nm. We attribute these structural changes to the PS surface charge unbalance due to LPS insertion. Consecutively, damaged surfactant/LPS 10% was incubated with peptide-based antibiotic PxB. We found that even a small dose of the cationic antibiotic reduces the repeat distance. PS/LPS incubated with 0.5% of PxB for 30 min reduced the repeat distance to $d \sim 8.6$ nm (not shown). Cationic molecule of PxB acts as an inhibitor of structural disarrangement induced by LPS and restores original lamellar packing. Structural changes were confirmed also by optical microscopy.

The study was focused on the mechanism underlying the structural changes in surface-reducing features (for details, see Kolomaznik et al., 2018). The function of 'infected' and consecutively 'treated' PS was tested with pulsating bubble surfactometer. The infected PS (surfactant/LPS 10%) was not able to reach the necessary physiologically relevant low surface tension. Intriguingly, the minimal surface tension decreased alongside with structural recovery when applying PxB (Kolomaznik et al., 2018). The obtained results accurately reflect the situation with a native lung surfactant as confirmed by a recent *in vivo* study (Calkovska et al., 2021) and support the idea of PxB/Curosurf combined therapy in neonatal medicine.

CONCLUDING REMARKS

Amphiphilic molecules of lipids and surfactants self-assemble into structures of various morphologies ranging from micelles,

lamellar and non-lamellar phases to microemulsions. Each of these morphologies possesses its own unique physical properties and offers the possibility for pharmaceutical applications. In the text above, we demonstrated just a few examples of 'usability' of phospholipid bilayers: as a model membrane mimicking the lipid bilayer of bacterial membrane in an effort to unravel the mechanisms of AMPs' antimicrobial activity, as a carrier designed for genetic material delivery, and finally, a lipid mixture extracted from animal's lungs that is clinically used in neonatal medicine. Findings presented here result from the collaboration between several institutions and have been published to the full extent in Kolomaznik et al. (2018), Liskayová et al. (2019), Silva et al. (2013) and Silva et al. (2018).

ACKNOWLEDGEMENTS

The author thanks all the co-authors in references (Kolomaznik et al., 2018; Liskayová et al., 2019; Silva et al., 2013, 2018) for their fruitful collaboration. SAXS experiments were performed at BL11-NCD-SWEET beamline at Alba Synchrotron, Barcelona with the collaboration of ALBA staff and at A2 beamline, Doris synchrotron in Hamburg. The research leading to these results has received funding from the JINR project 04-4-1142-2021/2025 and grants from VEGA 1/0223/20, APVV-17-0250 and SK-PT-18-0032.

Phospholipid bilayers in model membranes and drug delivery systems: from physics to pharmacy

References

- [1] Calkovska A, Haegerstrand-Björkman M, Curstedt T. Restoration of surfactant activity by polymyxin B in lipopolysaccharide potentiated injury of immature rabbit lungs. Scientific Reports 2021; 11:22
- [2] Calkovska A, Linderholm B, Haegerstrand-Björkman M, Pelizzi N, Johansson J, Curstedt T. Phospholipid composition in synthetic surfactants is important for tidal volumes and alveolar stability in surfactant-treated preterm newborn rabbits. Neonatology 2016; 109: 177-185
- [3] Devínsky F, Lacko I, Nagy A, Krasnec Ľ. Amine oxides. I. Synthesis, 1H-n.m.r., and Infrared spectra of 4-alkylmorpholine-N-oxides. Chem. Pap. 1978; 32:106-115
- [4] Israelachvili JN, Mitchell DJ, Ninham BW. Theory of self-assembly of hydrocarbon amphiphiles into micelles and bilayers. J. Chem. Soc. Faraday Trans 2, Mol. Chem. Phys. 1976; 72:1525-1568
- [5] Kobayashi T, Tsukagoshi S, Sakurai K. Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210. Gann 1975; 66:719-720
- [6] Kolomaznik M, Liskayova G, Kanjakova N, Hubcik L, Uhrikova D, Calkovska A. The perturbation of pulmonary surfactant by bacterial lipopolysaccharide and its reversal by Polymyxin B: function and structure. Int. J. Mol. Sci. 2018; 19: 1964
- [7] Liskayová G, Hubčík L, Búcsi A, Fazekaš T, Martínez JC, Devínsky F, Pisárčik M, Hanulová M, Ritz S, Uhríková D. pH-sensitive N,N-dimethylalkane-1-amine N-oxides in DNA delivery: from structure to transfection efficiency. Langmuir 2019; 35: 13382-13395
- [8] Silva T, Adao R, Nazmi K, Bolscher JGM, Funari SS, Uhríková D, Bastos M. Structural diversity and mode of action on lipid membranes of three lactoferrin candidacidal peptides. Biochim. Biophys. Acta 2013; 1828:1329-1339
- [9] Silva T, Claro B, Silva BFB, Vale N, Gomes P, Gomes MS, Funari SS, Teixeira J, Uhríková D, Bastos M. Unravelling a mechanism of action for a cecropin -A-Mellitin hybrid antimicrobial peptide: the induced formation of multilamellar lipid stacks. Langmuir 2018; 34:2158-2170
- [10] Teixeira V, Feio MJ, Bastos M. Role of lipids in the interaction of antimicrobial peptides with membranes. Prog. Lipid Res. 2012; 51:149–177.



EUROPEAN PHARMACEUTICAL JOURNAL



Formulation And Evaluation of Tablets Compressed from Granules Prepared by Thermoplastic Granulation

Special Issue Article

Kloc D., Wolaschka T.[⊠], Ruttkay F.

Department of Pharmaceutical Technology, Pharmacognosy and Botany, University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 041 81 Košice, Slovak Republic

Received 15 June, 2021, accepted 17 June, 2021

Abstract The aim of this formulation study was to determine the effect of the binder used in the preparation of granules by thermoplastic granulation on the release of propranolol from experimental tablets. Another aim was to select suitable excipients and their ratio in the granules to ensure a trouble-free formulation of the tablets. This study proved that the binder affects the flow properties of the granules, disintegration of the tablets and, subsequently, also the method of drug release, which can be used for the preparation of tablets with modified or prolonged drug release.

Keywords thermoplastic granulation – propranolol dissolution – polyethylene glycol – cetyl stearyl alcohol

INTRODUCTION

The granulation technique and the binder have an essential influence not only on the granules properties, but also on the properties of the final dosage form. Thermoplastic granulation is a process in which solid particles are converted into agglomerates in the presence of a molten binder. Upon cooling, the binder solidifies again and forms solid bridges between the powder particles. By choosing the right binder material, it is possible to effectively influence the dissolution profile of the final product. When using hydrophilic binders, e.g., polyethylene glycols or poloxamers, a formulation with immediate release is obtained. Instead, lipophilic binders, like waxes, fatty acids or fatty alcohols, are used for manufacturing controlled-release formulations (Keen et al., 2015; Mamidi et al., 2021; Steffens et al., 2020). The aim of this formulation study was to determine the effect of the binder used in the preparation of granules by thermoplastic granulation on the release of propranolol from experimental tablets. Another aim was to select suitable excipients and their ratio in the granules to ensure a trouble-free formulation of the tablets.

MATERIALS AND METHODS

Chemicals

Propranolol (Fagron, Olomouc, Czech Republic), polyethylene glycol 1500 (PEG 1500) (Fagron), cetyl stearyl alcohol (CSA)

(Fagron), colloidal silicon dioxide (CSD) (Fagron), lactose (LAC) (Dr. Kulich Pharma, Hradec Králové, Czech Republic), microcrystalline cellulose (MCC) (Centralchem, Bratislava, Slovakia), concentrated hydrochloric acid (HCI) (Centralchem), potassium dihydrogen phosphate (KH_2PO_4) (Centralchem), stearic acid (Galvex, Banská Bystrica, Slovakia), sodium hydroxide (NaOH) (Mikrochem, Pezinok, Slovakia)

Granule preparation

Materials sifted through a 1.00-mm sieve were homogenised in a ceramic mortar with a rough base and a ceramic pestle. The granulation mixture was melted for 30 minutes at 80 °C in a Memmert UNB400 oven (Memmert, Schwabach, Germany). The mixture was stirred every 10 minutes. After cooling, the granulation mixture was extruded through a sieve with a mesh size of 1 mm. CSD and stearic acid were added extragranular to the resulting granules as glidants and antiadhesives. This way, we prepared four types of granules, A3, A4, B3 and B4, with the composition given in Table 1.

Determination of flowability

Fifty grams of granules was poured loosely into the hopper of Erweka GDT (ERWEKA GmbH, Heusenstamm, Germany). After start-up, the instrument recorded the time it took for

^{*} E-mail: tomas.wolaschka@uvlf.sk

a Open Access. © 2021 European Pharmaceutical Journal, published by Sciendo. COBYNC-ND This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Formulation And Evaluation of Tablets Compressed From Granules Prepared by Thermoplastic Granulation

	A3 (%)	A4 (%)	B3 (%)	B4 (%)
LAC	33	28	33	28
MCC	33	28	33	28
PEG 1500	28	38	-	-
CSA	-	-	28	38
Stearic acid	1.5	1.5	1.5	1.5
CSD	1.5	1.5	1.5	1.5
Propranolol	3	3	3	3

Table 1. Composition of granules in percentages by weight.

the sample to flow. The measurement was repeated 3 times for each sample.

Determination angle of repose

Fifty grams of granules was poured continuously onto the inside of the funnel, which was placed 4 cm above the presumed top of the cone. The granules was allowed to flow freely on a solid base. The height (*h*) and the radius (*r*) of the resulting cone were measured and the angle of repose was calculated using Equation 1. The test was repeated 3 times for each sample.

 $\alpha = \operatorname{arc} tg \frac{h}{r} \left[\right]^{\circ} \tag{1}$

Carr compressibility index and Hausner ratio

One hundred millilitres (V_0) of granules was poured freely into the measuring cylinder and its weight was measured. Subsequently, 10, 50 and 100 taps on the solid surface were performed, after which the compacted volume (V_f) was recorded. Based on the values V_0 and V_f after 100 taps, the compressibility index was calculated using Equation 2 and the Hausner ratio was calculated using Equation 3. The test was repeated 3 times with each sample.

Carr compressibility index = $100 \frac{V_0 - V_f}{V_0}$ (2)

Hausner ratio =
$$\frac{v_0}{v_{100}}$$
 (3)

Tablet preparation

Tablets were compressed on a Romaco AM 8 rotary press (Romaco, Milan, Italy). The compression pressure was approximately 85 MPa for all granules. The height of the upper die was set to 15 mm.

Weight uniformity of tablets

Weight uniformity of the prepared tablets was performed according to the European Pharmacopoeia 10.5 (European Pharmacopoeia, 2010).

Tablet disintegration

Tablet disintegration was evaluated using Erweka ZT3-2 (ERWEKA GmbH). One tablet was placed in each of the six tubes of the device and the medium was placed in a beaker. Also, 0.1 mol/l HCl and phosphate buffer with pH 6.8 were used as media. The whole system was tempered to 37 °C. In both media, the test was run for 60 minutes at a frequency of vertical movement of the hanging device with 30 oscillations per minute.

Basket tablet dissolution

A Hanson SR8 PLUS dissolution device (Teledyne Hanson Research, Chatsworth, CA, USA) was used to dissolve the tablets. The device consists of eight containers and baskets. Seven propranolol tablets were placed in the baskets, one on each basket. A tablet with the same excipients but without the drug was placed in the last one. The distance between the basket and the inner bottom of the container was 25 mm. The baskets with the tablet rotated about their own axis at a speed of 50 turns per minute. The whole system was tempered to 37 °C. At intervals of 5, 10, 15, 22, 30, 42, 55 65, 70, 75, 82, 105, 120, 180, 240, 300, 360, 540, 720 and 1440 minutes, 2 ml of solution was collected from each of the eight vessels using a syringe with a needle into the prepared microtubes. The missing 2 ml of solution was replaced with pure dissolution liquid. The dissolution medium consisted of 750 ml of 0.1 mol/l HCl, to which a mixture of 46 ml of 0.2 mol/l NaOH, 200 ml of 0.2 mol/l KH_2PO_4 and $4 mIH_2O$ was added after 60 minutes of dissolution. The amount of propranolol in the samples was determined spectrophotometrically at a wavelength of 290 nm with the spectrophotometer Cary 60 (Agilent technologies, Santa Clara, CA, USA). Korsmeyer-Peppas dissolution model was used to describe the release kinetics from the tablets.

RESULTS AND DISCUSSION

In this formulation study, four types of granules were prepared by thermoplastic granulation. Granules A3 and A4 contained PEG 1500 and granules B3 and B4 contained CSA as the binder. PEGs are stable hydrophilic substances that are widely used in different types of pharmaceutical formulations, including parenteral, topical, ophthalmic, oral and rectal dosage forms. In solid drug formulations, PEGs with high molecular weight are used as binders in granulation to provide strength and plasticity to the granules. At high concentrations, they have the ability to prolong disintegration, which can be used to prepare dosage forms with delayed disintegration time. On the other hand, CSA is a lipophilic mixture of solid aliphatic alcohols consisting mainly of stearyl alcohols and cetyl alcohols. CSA is used mainly in cosmetics and topical pharmaceuticals. In addition, CSA can be used to control or slow the dissolution rate of tablets containing well or sparingly water-soluble drugs (Rowe et al., 2009).



Figure 1. Dissolution profile of tablets A3, B3 in the acidic medium.



Figure 2. Dissolution profile of tablets A4, B4 in the acidic medium.

The prerequisites for tablet compression without technological problems are good flow properties of the powders or granules. Therefore, in this study, extragranular excipients were added to the base granules. CSD, which is widely used in the manufacture of powders, capsules and tablets, has been used as a lubricant; while it improves the flow properties of powders, it also has a beneficial effect on the mechanical properties and disintegration of tablets. Stearic acid was used to prevent the tablet from sticking to the dies (Jonat et al., 2006, Komárek et al., 2006). After addition of extragranular excipients, the flowability of samples A3, A4, B3 and B4 was 6.60 ± 0.00 , 15.73 ± 0.3 , $6.93 \pm$ 0.23 and 15.47 \pm 0.42 seconds. It follows that the flowability was affected by the amount of binder and not its character. Angle of repose of samples A3, A4, B3 was 34.14° ± 0.04°,



Figure 3. Dissolution profile of tablets A3, B3 during the whole time dissolution.

 $34.81^{\circ} \pm 0.00^{\circ}$, $35.09^{\circ} \pm 0.05^{\circ}$, which represents good flow properties of the granules. For sample B4 with the angle of repose $36.57^{\circ} \pm 0.01^{\circ}$, the flow property was adequate. The Carr compressibility index of samples A3, A4, B3 and B4 was 9%, 10%, 15% and 11% and the Hausner ratio was 1.10, 1.11, 1.18 and 1.12. These values show that the flow character was excellent in samples A3 and A4, good in sample B3 and adequate in sample B4.

The preparation of tablets from these granules did not cause technological problems, the dies were filled sufficiently, and there was no sticking of the tablets to the walls of the die and the surface of the dies. At the same press setting, the average weight of the tablets was A3, A4, B3, B4, 567, 534, 628 and 629 mg. Each batch of tablets passed the weight uniformity test, where the average deviation for all types of tablets was between 1% and 2%. In the disintegration test, tablets A3, A4 and B3 disintegrated completely in HCl as well as in buffer within 60 minutes. B4 tablets retained their shape in both liquids throughout the test.

Dissolution profiles clearly showed that the drug was released significantly faster from tablets A3 and A4, for which the release half-life was calculated to be 12.56 ± 6.10 and 19.10 ± 2.31 minutes. The faster drug release was due to the hydrophilic properties of PEG. In the aqueous solution, water was transferred to PEG, which led to disintegration of the tablets. In contrast, the release half-life of propranolol for tablets B3 and B4 was 186.17 \pm 9.90 and 332.44 \pm 27.47 minutes. Due to the lipophilicity of CSA, the drug was released gradually because the dissolution fluid transfer was not accelerated by the hydrophilicity of the binder. The difference in the release rate of propranolol depending on the binder is clearly seen on the dissolution curves in acidic HCI medium (Figs 1 and 2) and during the whole dissolution time (60 minutes HCl + remaining time in phosphate buffer with pH 6.8) as shown in the graphs in Figs 3 and 4.

Formulation And Evaluation of Tablets Compressed From Granules Prepared by Thermoplastic Granulation



Figure 4. Dissolution profile of tablets A4, B4 during the whole time dissolution.

The effect of binder concentration on the release of propranolol from tablets was evaluated using a difference factor (f_1) and a similarity factor (f_2) . The difference factor (f_1) measures the percent error between two curves over all time points. The percent error is zero when the test and drug reference profiles are identical and increases proportionally with the dissimilarity between the two dissolution profiles. The similarity factor is a logarithmic transformation of the sum-squared error of differences between the test and reference samples over all time points. The f_2 can take values between 0 and 100. A value of 100 means that the dissolution profiles are identical and a value of 0 indicates a complete mismatch in the dissolution profiles. The similarity factor and

the difference factor were adopted by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as a criterion for assessing the similarity between two in vitro dissolution profiles. The FDA and the EMA consider the dissolution profiles to be similar if f, is less than 15 and f, is greater than 50 (Costa and Sousa Lobo, 2001). When comparing samples A4 (reference sample) and A3 (test sample), the value of f, was 7.77 \pm 2.66 and f, was 54.47 \pm 9.89. It follows that the drug release from these samples is similar. From this, it can be concluded that the concentration of PEG 1500 did not have a significant effect on the release of propranolol from the experimental tablets. When comparing the dissolution profiles of tablets B3 (test sample) and B4 (reference sample), the values of f_1 and f_2 were 26.87 \pm 1.64 and 41.18 ± 1.65 , which differs slightly from the values at which it can be argued that the dissolution profiles are similar. Based on these values, it can be concluded that the concentration of CSA slightly affects the release of propranolol from the experimental tablets.

This formulation study has shown that the character and concentration of the binder affects the properties of the granules and tablets. The binder affects the flow properties of granules, disintegration of the tablets and, subsequently, also the method of drug release, which can be used for the preparation of tablets with modified or prolonged drug release.

ACKNOWLEDGMENT

The work was designed thanks to the support provided by the project from the structural fund, "Renewal of research and development infrastructure and instrumentation at UVLF, ITMS 26210120028."

References

- Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Vol. 13, European Journal of Pharmaceutical Sciences. Elsevier; 2001. p. 123–33.
- [2] European Pharmacopoeia. Uniformity of mass of single-dose preparations. Eur Pharmacopoeia. 2010;(1):291–2.
- [3] Jonat S, Albers P, Gray A, Schmidt PC. Investigation of the glidant properties of compacted colloidal silicon dioxide by angle of repose and X-ray photoelectron spectroscopy. Eur J Pharm Biopharm. 2006;63(3):356–9.
- [4] Keen JM, Foley CJ, Hughey JR, Bennett RC, Jannin V, Rosiaux Y, et al. Continuous twin screw melt granulation of glyceryl behenate: Development of controlled release tramadol hydrochloride tablets for improved safety. Int J Pharm [Internet]. Elsevier B.V.; 2015;487(1–2):72–80. Available from: http://dx.doi.org/10.1016/j. ijpharm.2015.03.058
- [5] Komárek P, Rabišková M, Chalabala M, Kopecký F, Vitková M, Řehula M, et al. Technologie léku. Praha: Galén; 2006.

- [6] Mamidi HK, Palekar S, Nukala PK, Mishra SM, Patki M, Fu Y, et al. Process optimization of twin-screw melt granulation of fenofibrate using design of experiment (DoE). Int J Pharm [Internet]. Elsevier B.V.; 2021;593(September 2020):120101. Available from: https://doi.org/10.1016/j.ijpharm.2020.120101
- [7] Rowe RC, Sheskey PJ, and Owen SC. Handbook of pharmaceutical excipients. London: Pharmaceutical Press; 2006.
- [8] Steffens KE, Brenner MB, Hartig MU, Monschke M, Wagner KG. Melt granulation: A comparison of granules produced via highshear mixing and twin-screw granulation. Int J Pharm [Internet]. Elsevier B.V.; 2020;591(March):119941. Available from: https:// doi.org/10.1016/j.ijpharm.2020.119941

EUROPEAN PHARMACEUTICAL JOURNAL



Purification of Murine Gammaherpesvirus 68 With Use of Differential Centrifugation

Special Issue Article

Hodoši R.¹, Nováková E.^{1,2}, Šupolíková M.^{1,3}

¹Department of Microbiology and Virology, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovičova 6, Mlynská dolina, 842 15, Bratislava, Slovak republic ²Slovak Academy of Sciences, Biomedical Research Center, Institute of Virology, Dúbravská cesta 9, 845 05 Bratislava, Slovak republic ³Department of Galenic Pharmacy, Comenius University in Bratislava, Odbojárov 10 832 32 Bratislava 3, Slovak Republic

Received 14 June, 2021, accepted 17 June, 2021

Abstract The method for separation of viral particles in a concentrated form from the environment is called virus purification. Viruses are required to be purified for a range of studies in which it is necessary to distinguish the properties or structure of a virus from the host cells or culture media, including analysis of viral polypeptide structures and membrane glycoprotein function. Our objective was to purify murine gammaherpesvirus 68 (MHV-68, MuHV-4) using the centrifuge, equipment and other materials available in our laboratory. After infection of baby hamster kidney 21 (BHK-21) cells with MHV-68 with the multiplicity of infection (MI) of 0.01 and following virus multiplication, we repeatedly froze and thawed the cell culture to disrupt the cells and release the virus particles into the culture medium. We used low-speed centrifugation (3000 rpm at 4°C) to separate the viral particles from cell debris. Subsequently, we transferred the supernatant containing virus particles to a fresh centrifugation durations of 2, 4, 6 and 8 hours. To evaluate the quality of the obtained purified MHV-68 virus by this method and compare it to purified MHV-68 sample acquired by conventional ultracentrifugation on sucrose cushion (30%, w/v), we used the SDS-PAGE separation method using a 4%–20% (w/v) and 6%–14% (w/v) gradient gel. We obtained the best results with 6-hour-long centrifugation at 11,000 rpm. In conclusion, we managed to optimise virus purification method using the equipment available in our laboratory and prepared purified MHV-68 virus proteins.

Keywords MHV-68 – purification – virus proteins – SDS-PAGE

INTRODUCTION

The aim of the virus purification method is to separate it from all particles of cellular origin and culture media (Mistríková *et al.*, 2016). Viruses need to be purified for many studies in which it is necessary to distinguish the properties or structure of a virus from the properties or structure of host cells (or culture media), such as analysis of the structure of viral polypeptides or the function of membrane glycoproteins (Killington *et al.*, 1996). Differential (ultra)centrifugation (Fig. 1) is a common technique used to purify particles of defined size (i.e., virions). It is based on differences in the sedimentation rate of particles in suspension, which depends not only on their size, density and morphology, but also on the properties of the medium in which the virions are located and the force applied during centrifugation (Killington *et al.*, 1996; Taulbe and Furst, 2005). By using a density gradient centrifugation technique (particle separation is achieved by density gradient sedimentation), it is possible to achieve a more accurate separation of biological particles of similar dimensions but different densities. A large number of gradient materials are available, such as various dextrans and sucrose, or commercially available, for example, Percoll, Ficoll and others (Taulbe and Furst, 2005). The aim of our experimental work in the presented paper was to prepare purified murine gammaherpesvirus 68 (MHV-68, MuHV-4) propagated on the stabilised baby hamster kidney 21 (BHK-21) cell line and use it for further research. Using laboratory instrumentation, ultracentrifuge and other necessary materials available in our laboratory, we performed and optimised the MHV-68 purification method.

^{*} E-mail: hodosi3@uniba.sk

a Open Access. © 2021 European Pharmaceutical Journal, published by Sciendo. COBY-NC-ND This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.



Figure 1. Diagram of particle behaviour during differential centrifugation and density gradient centrifugation. a) During the differential centrifugation of a suspension of particles in a centrifugal field, the movement of the particles depends on their density, shape and size. b) To separate the biological particles by means of a density gradient, the samples are layered on the prepared gradient before centrifugation. To achieve separation, the sample is centrifuged, until the isopycnic position for the desired particles in the gradient is achieved.

MATERIALS AND METHODS

We used baby hamster kidney 21 (BHK-21) cells to propagate MHV-68 virus. Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) medium (Lonza, Belgium) supplemented with 7% fetal bovine serum (FBS; Sigma Aldrich, USA), 1% PSA (antibiotics - 100 U/ml penicillin-streptomycin and 100 µg/ml amphotericin) and 1% glutamine (Sigma Aldrich, USA) at 37°C in the presence of 5% CO². After virus adsorption, we replaced DMEM with 7% FBS with DMEM with 2% FBS. Cells were infected with MHV-68 virus at a multiplicity of infection of 0.1 and cultured until a cytopathic effect was developed. The virus/cell suspension was frozen and thawed 3 times (-80°C). We transferred the virus-medium solution from the culture flasks to 50-ml centrifuge tubes and centrifuged for 30 min at 2000 rpm at 4°C (low-speed centrifugation to remove cell debris). After centrifugation, we transferred the supernatant to a new centrifuge tube and centrifuged. We tested four different durations of 2, 4, 6 and 8 hours and two different centrifugation speeds of 8000 rpm (8801 g) and 11,000 rpm (16,639 g) at 4°C in an Eppendorf 5804 R centrifuge with an FA-45-6-30 rotor - primary high-speed centrifugation. After this centrifugation, we removed the supernatant, resuspended the pellet in 25 ml phosphate-buffered saline (PBS) and centrifuged for 2 hours at 11,000 rpm (16,639 g) at 4°C (secondary high-speed centrifugation) in an Eppendorf 5804 R centrifuge with an FA-45-6-30 rotor. After removing

the supernatant, we resuspended the virus pellet in 1 ml PBS, filled into microtubes in volume of 100 μ l and froze at -80° C. The purification process is schematically shown in Fig. 2. To evaluate the quality of the obtained samples, we used the sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) separation method using a gradient gel. To create a gradient separating gel, we prepared two bis-acrylamide solutions with different densities: one with the lowest gradient density (4% w/v and 6% w/v) and the second one with the highest gradient density (20% w/v and 16% w/v). Following this, we drew up the lower density solution (4% w/v and 6% w/v) into a serological pipette and then a higher density solution (20% w/v and 16% w/v) in the ratio of 1:1. The total volume must correspond to the volume of the gel cast (BioRad mini-PROTEAN gel cast has a volume of 5 ml). Next, we drew up approximately 1 ml of air into the serological pipette containing gel solutions and allowed the air bubble to ascend to the surface. The air bubble travel mixes the solution and forms a density gradient within pipette. Lastly, we applied the solution to the cast evenly and overlaid it with 99.6% w/v isopropanol and let it polymerise.

RESULTS AND DISCUSSION

For viral protein separation, we used gradient SDS-PAGE in the density range of 4%-20% (w/v) and 6%-16% (w/v),



Figure 2. Schematic diagram of virus purification steps.



Figure 3. Polypeptide profile of purified MHV-68 in gradient SDS-PAGE (6%–14%, w/v). Lane 1: ladder (Precision Plus Protein[®] Dual Xtra); lane 2: purified MHV-68 (centrifuged 6 hours) – 10 μ l/ lane; lane 3: purified MHV-68 (centrifuged 6 hours) – 5 μ l/lane; lane 4: purified MHV-68 (centrifuged 6 hours) – 3 μ l/lane.

considering the large range of molecular weights of the individual MHV-68 proteins (from 15 to 240 kDa). Samples obtained by centrifugation at 8000 rpm were unsuitable for further analysis due to insufficient concentration of MHV-68 proteins (data not shown). We obtained improved results by increasing the centrifugation speed to 11,000 rpm. Centrifugation of 2 and 4 hours was not sufficient to concentrate the virus in the pellet (data not shown). By extending the centrifugation interval to 6 hours, we obtained MHV-68 purification at a sufficient concentration, resulting in a polypeptide profile of viral proteins of specific size. We applied purified MHV-68 after 6-hour-long centrifugation at 11,000 rpm in various volumes on gradient SDS-PAGE with a density range of 6%-14% (w/v) (Fig. 3). Protein profile of purified murine gammaherpesvirus obtained by ultracentrifugation on sucrose cushion (Reichel et al., 1991) was comparable to MHV-68 purified by our method (after 6-hour-long centrifugation at 11,000 rpm).



Figure 4. Molecular weights (in kDa) of viral proteins of purified MHV-68, gradient SDS-PAGE (6%–14% w/v). Lane 1: ladder (Precision Plus Protein[®] Dual Xtra); lane 2: purified MHV-68 (centrifuged 6 hours) – 12 μ l/lane; lane 3: purified MHV-68 (centrifuged 6 hours) – 6 μ l/lane.

The next step was to determine the approximate molecular weight (in kDa) of the viral proteins of the obtained purified MHV-68. Fig. 4 shows in more detail the protein profile of the obtained purified MHV-68. We determined the molecular weight of individual proteins according to Reichel et al. (1991). In conclusion, we were able to prepare purified MHV-68 virus and determine the approximate molecular weight of viral proteins using available instruments and methods in our laboratory. We obtained the best results with primary centrifugation duration of 6 hours at a centrifugation speed of 11,000 rpm (16,639 g) at 4°C (in our case, 6 hours of primary and 2 hours of secondary high-speed centrifugation was sufficient to purify MHV-68 virus).

ACKNOWLEDGMENT

This research was carried out with the financial support from VEGA 1/0061/18 and UK/240/2021.

References

- [1] Mistríková M., Stančeková M., Kostrábová A. (2016) Základné laboratórne techniky používané vo virológii. 3. prepracované vydanie, Bratislava, Univerzita Komenského, strany 39-41, ISBN 9788022342087
- Killington R.A., Stokes A., Hierholzer J.C. (1996) 4-Virus purification.
 In: Mahy B.W.J. (ed.), Kangro H.O. (ed.), Virology Methods Manual, Academic Press, strany 71-89, ISBN 9780124653306
- [3] Taulbee D.N., Furst A. (2005) Centrifugation | Preparative. In: Worsfold P. (ed.), Townshend A. (ed.), Poole C (ed.), Encyclopedia of Analytical Science (Second Edition), Elsevier, strany 469-481, ISBN 9780123693976
- [4] Reichel M, Matis J, Lesso J. Stancekova, M. (1991). Polypeptides synthesized in rabbit cells infected with murine herpesvirus (MHV): a comparison of proteins specified by various MHV strains. Acta virologiea 35, 268 275



EUROPEAN PHARMACEUTICAL JOURNAL

Rohaľová S., Guman M., Wolaschka T.[⊠]

Transdermal Patches For Delivery of Beta-Blockers

Special Issue Article

Department of Pharmaceutical Technology, Pharmacognosy and Botany, University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 041 81 Košice, Slovak Republic

Received 15 June, 2021, accepted 17 June, 2021

Abstract Transdermal matrices containing 1.258 mg/cm² of propranolol and consisting of ethylcellulose (EC), castor oil, and hydroxypropylmethylcellulose (HPMC) or halloysite (HA) were prepared. They were evaluated by tests such as folding endurance, moisture content and absorption, and paddle dissolution test. Of the total amount of propranolol in the samples (20 mg), 28.41% \pm 3.30% was released from the EC film after 24 hours, the addition of HA 20.94% \pm 1.52% (f₁ = 61.82 \pm 7.70, f₂ = 53.61 \pm 4.25) or HPMC 36.05% \pm 6.18% (f₁ = 34.48 \pm 8.79, f₂ = 65.02 \pm 5.33). The dissolution profiles of HA and HPMC films were compared with each other (f₁ = 51.35 \pm 12.56, f₂ = 59.20 \pm 9.43).

Keywords ethylcellulose - halloysite - hypromellose - propranolol - transdermal therapeutic system

INTRODUCTION

Beta-blockers are one of the most used molecules in the therapy of cardiovascular diseases. They are mainly formulated as conventional dosage forms (Aguil et al., 2006). Management of cardiovascular diseases often requires, besides a change of lifestyle, also a long-term pharmacotherapy. This kind of therapy can lead to insufficient patient compliance because of dosage frequency. Orally administered beta-blockers are characterised by the need for doses that are more frequent, significant first-pass effects and variable bioavailability. Transdermal patches prolong the time interval of therapeutic plasma levels, which decreases the incidence of side effects and the dosage frequency. Transdermally administered drugs avoid the hepatic first-pass effect, which increases their bioavailability. Another advantage of transdermal patches is their easy application, which can also contribute to higher patient compliance (Ahad et al., 2015).

Model drug propranolol is significantly hepatically metabolised, which causes low bioavailability 30%–35% after oral administration. Its elimination half-life is 2–6 hours and the partition coefficient logP is 3.03 (Calatayud-Pascual et al., 2018). Thanks to these properties, propranolol is suitable for transdermal administration.

METHODS

Chemicals: Propranolol hydrochloride was purchased from Fagron, a.s. (Olomouc, Czech Republic), ethylcellulose (EC) from Acros Organics (New Jersey, PA, USA), hydroxypropylmethylcellulose (HPMC) from Dr. Kulich Pharma, s.r.o (Hradec Králové, Czech Republic) and halloysite (HA) nanoclay from Aldrich Chemistry (Saint-Louis, MO, USA). Film preparation was carried out by solvent casting method. Composition of the films is shown in Table 1. The dispersions were prepared by mixing EC in ethanol with castor oil as a plasticiser for 5 minutes at 750 rpm. Propranolol was dissolved in ethanol and added to the dispersion. Either HPMC or HA was added to the prepared dispersions and the mixing was continued for 15 minutes at 750 rpm. Films were poured into Petri dishes previously wiped out with glycerine. HA-containing films underwent incorporation of the drug in a vacuum, which was applied 3 times for 5 minutes. Films were dried (UNB400; Memmert, Schwabach, Germany) after 12 hours at 60 °C and covered with funnels.

Folding endurance was determined by repeatedly folding the film at the same place until visible damage was caused. The number of times the films could be folded without breaking gives the folding endurance value. We considered

^{*} E-mail: tomas.wolaschka@uvlf.sk

³ Open Access. © 2021 European Pharmaceutical Journal, published by Sciendo. CC) BYANCAND This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Transdermal Patches For Delivery of Beta-Blockers

Film	Propranolol	Ethanol	Castor oil	Ethylcellulose	Halloysite	Hypromellose
E	0.02	10	0.162	0.36	-	-
Ha1	0.02	10	0.162	0.36	0.0225	-
Ha2	0.02	10	0.162	0.36	0.0450	-
HPMC1	0.02	10	0.162	0.36		0.0225
HPMC2	0.02	10	0.162	0.36		0.0450

Table 1. Composition of formulations (in grams).

the film as favourable if it lasted without obvious damage after a hundred folds (Sanap et al., 2008).

Percentage moisture content was calculated using Equation (1), where m_1 is the initial weight of a film and m_2 is the final weight of the same film after being kept in a desiccator with silica gel for 24 hours at room temperature (Arora & Mukherjee, 2002).

$$\% = \frac{m_1 - m_2}{m_2} \ 100 \tag{1}$$

Percentage moisture uptake was calculated using Equation (2), where m_1 is the initial weight of a film and m_2 is the final weight of the same film after being kept in a desiccator with a saturated solution of sodium chloride instead of potassium chloride for 24 hours at room temperature (Arora & Mukherjee, 2002).

$$\% = \frac{m_2 - m_1}{m_1} \ 100 \tag{2}$$

Dissolution test was carried out using a paddle apparatus (50 rpm) with the addition of a modified disc assembly in acetate buffer with pH 4.5 tempered at $32 \degree C \pm 0.5 \degree C$ (Ph. Eur. 10.4, 2021). Fourteen samples were collected for 24 hours (SR8 Plus; Hanson Research, Los Angeles, CA, USA).

RESULTS AND DISCUSSION

Folding endurance was the main criterion taken into consideration when formulating the films. Firstly, it was noted that EC films require a plasticiser. Out of castor oil, polyethylene glycol and glycerine, the addition of 0.162 g of castor oil increased the number of folds to 100. Moreover, the amount of EC was increased to 0.36 g to obtain more compact and flexible films. These films remained intact after 400 folds. For homogeneity of the films, it was necessary to direct the evaporating ethanol into a funnel during the drying process. The addition of 0.0225 or 0.045 g of HPMC caused 0.85% (p = 0.004) or 0.95% (p = 0.002) increase in moisture content and 0.95% (p = 0.278) and 1.93% (p = 0.078) increase in

moisture uptake, respectively. In our case, similar to what Dey et al. (2009) had mentioned, HPMC as a hydrophilic polymer increased the water content. HA addition did not cause a statistically significant difference in either moisture content or uptake.

We monitored the amount of propranolol released by dissolution in acetate buffer of pH 4.5 for 24 hours and calculated the similarity (f₂) and difference (f₁) factors to compare the dissolution profiles. Of the total amount of propranolol in the samples, 28.41% ± 3.30% was released from the EC film after 24 hours, the addition of HA 20.94% \pm 1.52% (f₁ = 61.82 \pm 7.70, f₂ = 53.61 \pm 4.25) (Fig. 1) or HPMC $36.05\% \pm 6.18\%$ (f₁ = 34.48 ± 8.79 , f₂ = 65.02 ± 5.33) (Fig. 2). The dissolution profiles of Ha1 and HPMC1 films were compared with each other ($f_1 = 51.35 \pm 12.56$, $f_2 = 59.20 \pm 9.43$). The Food and Drug Administration and the European Medicines Agency consider the dissolution profiles to be similar if f, is less than 15 and f₂ is greater than 50 (Costa & Sousa Lobo, 2001). All similarity factors of the dissolution profiles of the films were above 50, and also, all difference factors were considerably above 15; we can therefore conclude that these profiles are not similar.

According to the coefficient of determination (R_{γ}) , the drug followed Higuchi model in case of HPMC1 film ($R_2 = 0.9805 \pm$ 0.0057) and Korsmeyer–Peppas model in case of Ha1 film ($R_2 =$ 0.9715 ± 0.0032). Release exponents (n) of Ha and HPMC films were in the range 0.5 < n < 1.0, which indicates non-Fickian diffusion of the drug. Based on the percentage of propranolol released from the formulations and their dissolution profiles, it can be stated that HA and HPMC are release rate modifiers in the prepared films. As Dey et al. (2009) had stated, the introduction of hydrophilic HPMC increased the dissolution rate in the case of water-soluble propranolol. However, such small amount of HPMC did not cause the initial burst effect unlike the case of the mentioned paper. HA is known for drug loading of cationic compounds and providing them prolonged release, possibly reducing the burst effect (Levis & Deasy, 2003). Both of these effects are demonstrated in Fig. 1. In conclusion, we have prepared matrix-type propranolol patches without adhesives, which, to our knowledge, is novel in terms of composition. We have confirmed the possibility of alteration of the dissolution rate with the use of excipients such as HPMC for increasing and HA for decreasing the



Figure 1. Dissolution profiles of formulations E and Ha1 compared.



Figure 2. Dissolution profiles of formulations E and HPMC1 compared.

dissolution rate. However, since the daily dose of propranolol usually starts at 40–80 mg, the enhancement of dissolution rate should be considered keeping in mind the possible burst effect of hydrophilic polymers.

ACKNOWLEDGEMENT

The work was supported by the project from the structural funds 'Renewal of research and development infrastructure and instrumentation at UVLF, ITMS 26210120028'.

Transdermal Patches For Delivery of Beta-Blockers

References

- Ahad A, Al-Jenoobi FI, Al-Mohizea AM, Akhtar N, Raish M, Aqil M. Systemic delivery of β-blockers via transdermal route for hypertension. Saudi Pharm J. 2015;23(6):587–602.
- [2] Aqil M, Sultana Y, Ali A. Transdermal delivery of β-blockers. Expert Opin Drug Deliv. 2006;3(3):405–18.
- [3] Arora P, Mukherjee B. Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. J Pharm Sci. 2002;91(9):2076–89.
- [4] Calatayud-Pascual MA, Sebastian-Morelló M, Balaguer-Fernández C, Delgado-Charro MB, López-Castellano A, Merino V. Influence of chemical enhancers and iontophoresis on the in vitro transdermal permeation of propranolol: Evaluation by dermatopharmacokinetics. Pharmaceutics. 2018;10(4).
- [5] Costa P, Sousa Lobo JM. Modeling and Comparison of Dissolution Profiles. Eur J Pharm Sci. 2001;13(2):123-133.
- [6] Dey BK, Kar PK, Nath LK. Formulation design, preparation and in vitro – in vivo evaluation of propranolol hydrochloride transdermal patches using hydrophilic and hydrophobic polymer complex. Research J. Pharm. and Tech. 2009;2(1):155–160.
- [7] European pharmacopoeia 10.4. 2.9.4. Dissolution test for transdermal patches. (https://pheur.edqm.eu/app/10-4/ content/10-4/20904E.htm?highlight=on&terms=dissolution). Revised April 2021. Accessed June 7, 2021.
- [8] Levis SR, Deasy PB. Use of coated microtubular halloysite for the sustained release of diltiazem hydrochloride and propranolol hydrochloride. Int J Pharm. 2003;253(1–2):145–57.
- [9] Sanap GS, Dama GY, Hande AS et al. Preparation of transdermal monolithic systems of indapamide by solvent casting method and the use of vegetable oils as permeation enhancer. Int J Green Pharm. 2008;2(2):129.